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                               ABSTRACT 
INTRODUCTION 
  Psoriasis is a chronic inflammatory skin disease characterized by hyper-
proliferation, abnormal differentiation, and inflammatory infiltration in 
epidermis and dermis. Angiogenesis or neovascularization refers to the 
formation of new capillary vessels from the existing vascular bed .Dermal 
microvascular expansion with abnormal orientation and dilatation of capillaries 
in the biopsies of the psoriatic skin revealed that the disease was angiogenesis 
dependent .  
AIM AND OBJECTIVES 
• to  analyse  immunohistochemical expression of  angiogenic factors 
Vascular  endothelial growth factor, Von wille brand  factor and CD 34 in 
skin biopsy of patients with psoriasis vulgaris and controls. 
• To compare the neovascularisation score of CD 34, VEGF and vWFr in 
skin biopsy of psoriasis vulgaris cases and controls. 
• To correlate the expression of angiogenic factors and  psoriasis area and 
severity clinical index(PASI SCORE) which is a measure of clinical 
severity . 
 
 
MATERIALS AND METHODS 
 This is a case control study carried over a period of 15 months from 
April 2013 to July 2014.Thirty two  psoriasis cases and thirty control healthy 
skin were studied.Biopsy specimen is taken from skin of newly diagnosed 
psoriasis and patients who have not taken any treatment two months prior to 
study. Histopathological examination of psoriasis vulgaris was confirmed. 
Immunohistochemical expression for VEGF(vascular endothelial growth 
factor), vonwillebrand factor and CD 34 was studied. 
RESULTS 
VEGF expression in epidermis was significantly higher in icases when 
compared to control skin (p=<o.o1).CD 34 expression was significantly 
upregulated in cases when compared to controls.(p<0.01). Whereas only weak 
expression of vonwillebrand factor was observed in both cases and controls. 
Significant correlation between the expression of VEGF and PASI 
score(r=0.944;p<0.05), and expression of CD 34 and PASI score was 
observed(r=0.942;p<0.05). 
CONCLUSION   
Significant overexpression of VEGF and CD 34 was noted in cases when 
compared to controls.The keratinocytes in the psoriatic skin lesions were 
recognized as a source of pro-angiogenic cytokines which induce angiogenesis, 
namely the vascular endothelial growth factor (VEGF) and other growth factors 
which promotes micrangiopathic modifications in psoriatic plaque. 
Angiogenesis plays an important role in genesis and development of psoriasis 
vulgaris. Therefore  development  of  targeted anti- angiogenic therapy  might 
be beneficial for this chronic disabling  dermatological disease. 
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INTRODUCTION 
 
Skin is the largest organ in the body composed of many 
interdependent cell structures.
1
 Direct visual examination of skin lesions, 
gross description and histopathology are necessary for diagnosis of 
dermatological lesions. 
Psoriasis is a chronic papulosquamous  dermatitis with varying 
incidence between 0.5% to 1.5% of population.
2
 Psoriasis is one of the 
common  type of dermatological condition  in India  with  an 
epidemiological and prevalence  characteristics being  similar to Western 
countries.
3
 The mean age of onset is around 25 years although milder 
form is seen in older persons.
4 
Psoriasis typically presents as well demarcated erythematous 
plaque covered by silvery white scales. It  more  frequently affects the 
skin of extensor aspect of elbows , lumbosacral region, knees, intergluteal 
cleft, scalp and glans penis region. There are several clinical variants of 
psoriasis. The chronic plaque type , also known as psoriasis vulgaris and 
other variants are guttate type of psoriasis, erthyrodermic type of  
psoriasis , pustular type of  psoriasis and flexural type psoriasis. Nail 
involvement and koebner reactions are seen in psoriasis patients. 
2 
 
The characteristic histopathological features are acanthosis, regular 
downward elongation of rete ridges, spongiform pustules and 
munro’smicroabscesses. Papillary dermis shows edema and tortuous 
dilated capillaries. These dilated tortuous capillaries are the source of  
bleeding points when the scales are scrapped off from the plaques.
5 
Psoriasis has a complex pathogenesis
6
 characterized by altered 
keratinocyte proliferation and differentiation,  immune mediated 
inflammation , dysregulated angiogenesis and vascular remodelling.
7
 
Various factors which  play  a central and pivotal  role in the 
pathomechanism  of psoriasis are Th1type of cell, Th17 cell, antigen 
presenting cell ,  Langerhan type of  cells, natural killer cell , 
keratinocytes  and macrophages  and various  cytokines of  Th1 type.
6 
New blood vessel formation is seen in  early stages of psoriatic 
lesions and  neovascularisation  disappears  with clearance of skin 
disease.
8
 Various  angiogenic  mediators such as vascular endothelial 
growth factor,  hypoxia inducible factor, and  several  proangiogenic 
cytokines like  tumour necrosis factor , interleukin 17 and interleukin 8, 
are increased in lesional skin of  psoriasis.
8
  
Psoriasis usually has a chronic course, albeit spontaneous or 
treatment induced remissions do occur. 
3 
 
In present study neovascularisation score in normal skin biopsy as 
compared to skin biopsy of psoriasis vulgaris patients is done using CD 
34. Also the expression of VEGF-vascular endothelial growth factor and 
vonwillebrand factor in epidermis of normal skin biopsy compared  to 
skin biopsy of psoriatic patients is done.  This attempts to prove that 
vascular changes appears to be significant in pathomechanism of 
psoriasis. Thus angiogenesis appears to contribute to the pathogenesis of 
psoriatic lesions.
9
                  
Anti angiogenic  agents may be potential targeted therapy in the 
future. 
The present study encompasses differential immunohistochemical 
expression of angiogenic factors namely vascular endothelial growth 
factor (VEGF) , Von willebrand factor  and CD 34 in lesional skin  of 
patients  with  psoriasis vulgaris. 
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AIMS AND OBJECTIVES 
• to  analyse  immunohistochemical expression of  angiogenic 
factors Vascular  endothelial growth factor, Von wille brand  factor 
and CD 34 in skin biopsy of patients with psoriasis vulgaris and 
controls. 
• To compare the neovascularisation score of CD 34, VEGF and 
vWFr in skin biopsy of psoriasis vulgaris cases and controls. 
• To correlate the expression of angiogenic factors  with  psoriasis 
area  severity index(PASI SCORE) which is a measure of clinical 
severity . 
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REVIEW OF LITERATURE 
  
ANATOMY AND HISTOLOGY OF SKIN 
 
Understanding normal skin histology is of prime importance to 
identify cutaneous pathology. It has two histologically and anatomically 
separate layers namely the epidermis and the dermis. But epidermis and 
dermis are functionally interdependent. There is subcutaneous adipose 
tissue below the dermis.  
The skin has many functions including mechanical protection, sun 
protection, temperature regulation, immune related functions, sensory 
perception  and  nutrient metabolism.
10  
The epidermal keratinocyte has 
been recognised as a potent source of immunogenic molecules such as 
interleukins, colony stimulating factors , interferons, transforming growth 
factors, tumour necrosis factor  and growth factors
11 
 
EPIDERMIS 
Epidermis is predominantly composed of stratified squamous 
epithelial cells known as keratinocytes. Other types of cells in epidermis 
are Langerhans cells, Neuroendocrine cells ( Merkel cells) , unmyelinated 
axons and melanocytes. Keratinocytes differ from other cell types by 
large size, abundant stainable cytoplasm and intercellular bridges.
10
  
6 
 
The keratinocytes are organised into four layers – stratum basale ,  
spinosum,  granulosum,  lucidum and  corneum. 
 STRATUM BASALE (basal layer) 
The basal cell layer  is the lowermost  layer of  epidermis. It has 
single row of  cells of cuboidal type. These cells have round to ovoid 
nuclei with basophilic cytoplasm and often contain melanin pigmentation 
from adjacent melanocytes.
10
   The basal layer rests on a basement 
membrane which separates epidermis from dermis. Basal layer is 
composed of mitotically active cells which give rise to other 
keratinocytes. 
Individual cells are attached to each other by desmosomes and 
attachment to basement membrane by hemidesmosomes.
10 
 Cells in the 
basal layer contain  intermediate filaments and they increase in number as 
they move upward. 
STRATUM  SPINOSUM (squamous layer) 
This second layer  which consists of four to six rows of cells is just 
above the basal layer. Cells in this layer shrink during routine histologic 
preparations. Thus the intercellular spaces appears to form numerous 
cytoplasmic extensions or  spines. The spines represent the sites where 
desmosomes are anchored to bundles of tonofilaments. These 
7 
 
tonofilaments provide tensile strength against abrasion of epidermis. The 
intercellular spaces contain acid mucopolysaccharides and neutral 
mucopolysaccharides. Hyaluronic acid an important component of acid 
mucopolysaccarides, is abundant in intercellular spaces of stratum 
spinosum.
12 
STRATUM  GRANULOSUM (granular layer) 
This third layer consists of three to five rows of flattened cells. 
This  layer is seen just above stratum spinosum.  Cells in this stratum 
granulosum are filled with dense keratohyaline granules. The granular 
cell layer is the mature keratin forming transition zone of epidermis.
10
 
Dissolution of nucleus and cell organelles is starts from this granular cell 
layer. Diffusely staining lysosomal enzymes in this layer plays an 
important role in autolytic changes in this layer.
13 
STRATUM LUCIDUM 
Stratum lucidum consists of row of tightly packed flattened cells 
that lack nuclei or organelles. This layer is seen only in thick skin. Cells 
in this layer contains densely packed keratin filaments. 
STRATUM CORNEUM (horny layer)  
The horny layer  is the superficial layer of  the epidermis and 
consists of flattened dead cells. These  cells are anucleate and  filled with 
8 
 
soft keratin. The superficial keratinised cells are shed or desquamated 
continuously  and replenished by cells arising from deeper most basal 
layer or stratum basale. The horny cytoplasm of these cells contain 
cystine disulfide bonds, these shrink on formalin fixation and form a shell 
along cell membrane resulting in basket weave appearance in routine  
histologic sections.
14 
DERMIS 
Dermis is seen just below epidermis and consists of connective 
tissue fibers and cellular components of epidermis. The cellular 
components are fibroblasts,dermal dendritic cells ,macrophages and mast 
cells. The extracellular components are collagen,elastic fibers and ground 
substance.
10 
The pale staining narrow zone of connective tissue just below the 
dermis is papillary dermis. The papillary dermis indents the basement 
membrane of epidermis to form dermal papillae. The reticular layer of 
dermis comprises the rest of dermis. The reticular dermis forms the bulk 
of dermis. The reticular dermis  predominantly consists of dense  
connective tissue.  
The dermal connective tissue consists of numerous  blood vessels , 
nerves and  lymph vessels. The  dermis is highly vascular. In dermis there 
9 
 
are numerous sensory receptor which are meissner’s corpuscles located 
closer to dermal papillae and pacinian corpuscles which are found deeper 
in connective tissue of dermis . Though  skin appendages such as hair 
follicle and sweat glands develop from epidermis ,they are located in 
dermis. 
HISTORICAL PERSPECTIVE OF PSORIASIS 
Psoriasis is one of the common dermatological disease . Thus  it is 
justified to have some knowledge in history of psoriasis. 
The history of psoriasis, remained speculative for the time before 
Willan (1757-1812), and  reliably assigned only for the last 200 years.  
Robert Willan (1757- 1812) described different types of psoriasis. Hebra 
(1806-1880) gave a morphological definition, in which histopathology 
feature was also taken into account. 
In the early 20th century, the biochemistry and histochemistry of 
psoriasis provided new insights. In the second half of the 20th century, 
immunocytochemistry and immunology threw some light on the 
pathogenesis of the disease. At the end of the 20th and at the beginning of 
the 21
st 
century, advent of genetics and immunology have opened up new 
therapeutic approaches due to the interesting insights into the 
pathogenesis of psoriasis.
15 
10 
 
PSORIASIS 
Psoriasis  is a one of the common , recurrent chronic inflammatory 
dermatological disease  which affects  about 2 % of the caucasian 
population
16 
and results in severe impairment of quality of life.
   
 
PREVALENCE 
The prevalence of psoriasis differs in various  parts of the world 
ranging  from 0% to 11.8%.
17,18,19,20. 
 The prevalence of psoriasis in India 
ranges from 0.44% to 2.8%. The disease is  two times   commonly seen in 
males when compared with females.  
GENETIC BASIS OF PSORIASIS 
The molecular genetics of psoriasis is complex and multiple genes 
are involved. Genetic transmission  plays  an important  role in 
etiopathogenesis of psoriasis.  There are seven major susceptibility loci  
being  reported for psoriasis.  Many studies have shown  that the  major 
susceptibility locus  is in chromosome  6p21, known as PSORS1 and is 
represented in most of the  populations.
 21-26
An association with various 
loci  was also  reported on chromosomes 1p (PSORS7)
25
, 1q 
(PSORS4)
27
, 3q (PSORS5)
28
, 4q (PSORS3)
29
, 17q (PSORS2)
30
, and 19p 
(PSORS6)
31
. Familial clustering of psoriasis cases are noted .
3
 Familial 
11 
 
incidence of psoriasis is higher in  childhood psoriasis than adult onset 
psoriasis.
32,33,34
 
Psoriasis vulgaris is associated with certain HLA antigens.
3 
Psoriasis is associated with HLA A1, B17 and Cw6.
35
 Association with 
HLABw57 and DR7 is seen in South India.
36
 HLA Cw *0602 is the main 
allele with higher frequency in North India.
37 
AGE DISTRIBUTION IN PSORIASIS 
Psoriasis tends to occur more commonly in third or fourth decade.
3 
The  age  of onset for psoriasis is bimodal distribution was  recognised in 
many studies. The  age  for the first clinical  presentation of psoriasis  
ranges  from 15 to 20 years of age,and a second peak  of onset which  
occurs at age of  55 to 60 years.
38-41
  Two types of psoriasis are seen, type 
one and two, that can be distinguished by a bimodal age distribution. 
Type 1 psoriasis has its onset  by the age of 40 years; Type II  psoriasis 
has its onset  after 40 years of age. Type I disease accounts for more than 
75% of cases.
41
 Patients with earlier age of  onset that is the type I 
psoriasis have a severe disease and many relatives are affected compared  
to  patients with later onset disease or the type II psoriasis. In  psoriasis 
cases with early onset of  skin lesions, strong  associations are being  
reported with human leucocyte antigen Cw6  
12 
 
TRIGGER FACTORS 
Various   modifiable  risk factors  predispose an  individual to 
develop  psoriasis or exacerbate  the already existing psoriatic disease. 
The  modifiable   risk factors  includes  smoking, intake of alcohol, 
obesity, dietary habits, several types of  infection ,drug intake  and 
stress.
42-51
 The actual mechanism  which  aggravates   psoriatic skin 
lesions  is  yet to be elucidated; 
Acute bacterial and viral infections are associated with  onset of 
psoriasis  or flaring up of the disease. Streptococcal infection  is also an 
aggravating  factor for  guttate psoriasis, more commonly in childhood 
age group and younger adults. Human immunodeficiency virus is also  
associated with an onset of severe plaque type of   psoriasis and  does not 
respond  to standard therapy or medications.  
Various drugs  which  includes beta blockers, lithium, antimalarial 
drugs, tetracycline, nonsteroidal antiinflammatory drugs  and  withdrawal  
of steroids  are  also  associated with the onset of  psoriasis  or flaring up 
of the   disease. Drug induced psoriasis is likely to occur  in  patients  
with  no past  history of psoriatic skin lesions which  regresses and clears 
after withdrawal of the causative medication. Drug aggravated psoriasis   
occurs  in patients who already have a history of psoriatic  skin lesions  
and progresses even after withdrawal of the causative drugs. The actual  
13 
 
mechanism of action by which a drug aggravates  psoriasis is not clearly  
understood. Studies  suggest that the mechanism by which beta blocker 
induced psoriatic skin lesion  occurs is due to blocking of epidermal beta 
2 receptor that leads to reduced cyclic adenosine monophosphate in the 
epidermis and hyperproliferation of  keratinocytes .  
The current thought in lithium aggravating psoriasis is by 
inhibition of  inositol monophosphate, resulting in decrease of intra 
cellular calcium levels and enhanced proliferation of epidermal 
keratinocytes. Also the  lithium  increases   tumor necrosis factor alpha 
production and IFN - gamma production in the  epidermal cells  and they  
play a major role in psoriasis.  
Antimalarial drugs  exacerbate  already  existing psoriasis in  40% 
of patients. It acts by inhibition of  the enzyme transglutaminase and 
causes proliferation of keratinocytes. The  relevance of antibiotic induced 
psoriatic skin lesions is still a controversy. The  tetracycline class of  
antibiotics  exacerbates psoriasis through decrease in  intracellular cyclic 
adenosine monophosphate.  Finally, NSAIDs inhibit the arachidonic acid 
metabolism  that  leads  to  accumulation of leukotrienes and these 
leukotrienes  aggravate  psoriasis.  
Knowledge  regarding the  drugs that induces or aggravates 
psoriasis is  of prime importance to prevent the precipitation of the  
14 
 
disease. Psychological stress disorder is also a trigger factor for  
psoriasis
42,52-55
. 
PATHOGENESIS OF PSORIASIS 
Cells like T lymphocyte cell, macrophages, (APC) antigen-
presenting cells, natural killer cells, epidermal keratinocytes,  Langerhans' 
cell, , various types of Th1  cytokines and various growth factors  such as 
(VEGF),  vascular endothelial growth factor,  (KGF) keratinocyte growth 
factor  play a major  role in  pathomechanism  of  psoriasis
6
. There is  
need to know current concepts and pathomechanisms of psoriasis 
CELLULAR BASIS -  PSORIASIS 
The psoriatic disease commences  with the activation of T 
lymphocyte  cell  towards  a gene product or an unknown antigen. 
Activation of T lymphocyte  depends upon  binding of  Tcell  with 
antigen presenting cell (APC) followed by expression of  the  T cell 
receptor also known as TCR.TCR identifies  the peptide  presented by the 
antigen presenting cell within the groove of Major histo compatibility 
complex. This  antigen stimulated activation  of T cell results in  
conversion of  naive T lymphocyte into an antigen specific T lymphocyte, 
that  develops into a memory  type of cell which  circulates in the whole 
body . Followed  by  the activation of  these T cells, an array of cytokines 
that is  granulocyte macrophage colony stimulating factor ( GMCSF), 
15 
 
EGF,interleukin-8, interleukin-12, interleukin-23, interleukin-17, 
interleukin-1, interleukin-6, Fractalkine, tumor necrosis factor-α and 
others are produced  by these  activated T lymphoctes. Due to the  effect 
of the above cytokines there is proliferation of epidermis and hyperplasia 
of epidermis, migration of neutrophils , increase in response of  Th-1 cell 
type, upregulation of adhesion molecules and angiogenesis,
6
 . 
ROLE OF KERATINOCYTE 
The type of cell which is  responsible for the onset of psoriasis is 
still a controversy. Various  investigations concentrated on epidermal 
keratinocytes. Aberrant activation of keratinocytes  and metabolism of   
keratinocytes in the epidermis, leads to increased  proliferation of 
keratinocytes and they  are the characteristic features in lesional psoriatic 
skin
56
.  Psoriatic skin has  eight times  shortened  turnover for  
keratinocytes due to enhanced  keratinocyte proliferation 
57.
  
   Studies have shown that in transgenic mice, deletion of the 
activator protein 1 family members such as Jun B and C Jun especially in 
keratinocytes of basal layer causes an inflammatory skin disease 
simulating  psoriatic skin lesions supporting the prime role of 
keratinocytes  triggering psoriatic skin lesions
58
. Recent studies show that  
in experimental mice ,the psoriatic skin lesions are associated  with 
altered expression of transcription factors of the activator protein-1  in  
16 
 
the epidermal cells. The cell cycle time  for  hyperproliferating  
keratinocytes in psoriasis  is of shorter duration. The  maturation and 
shedding of epidermal  keratinocyte  takes  atleast 26 days in normal skin, 
whereas it takes only 4 days for the epidermial keratinocyte  of  psoriatic 
skin lesions
59
.
 
 Growth factors produced by  various types of cell, are 
known to control the marked  keratinocyte  proliferation. 
KERATINOCYTE AND IMMUNE SYSTEM CROSS TALK 
There is a complex interaction between  immune system and 
keratinocytes as basic steps in the pathogenesis of psoriasis
60-65
. Studies 
in  transgenic mice shows that ubiquitous activation of  nuclear factor 
kappa beta  (NFkb) transcription factor, which  potentially  induces  
inflammatory responses, which  results in  development of  skin lesions 
resembling psoriasis, which includes hyperkeratosis, acanthosis, 
parakeratosis as well as  dilatation of dermal capillaries
64
. This psoriatic 
skin lesion is dependent on the simultaneous nuclear Factor  kappa beta  
activation in keratinocytes and T cells, because selective activation of the 
transcription factor  in keratinocytes or in T cells only is not adequate 
enough  to produce  these  specific dermatological and histopathological 
changes. This shows  the  prime importance of interaction between 
keratinocytes and T cells in  pathogenesis of psoriasis.  The   Langerhans 
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cells and Tcells  infiltrates into the epidermis, and  they come in contact 
directly with epidermal keratinocytes.  
The mononuclear cells which infiltrates the dermis secretes 
chemical mediators that induces  the proliferation of keratinocytes and 
endothelium. The dermal tissue  of psoriasis  skin lesion is infiltrated  by 
CD4 +  T helper type of cells and these T helper cells   secretes  
proinflammatory cytokines such as interferon-IFN-γ,interleukin-17 and  
tumor necrosis factor alpha. 
66,67 . 
Also the increased  levels of  cytokines 
such as IL-8, IL-6  and keratinocyte growth factor [transforming growth 
factor-alpha] are seen  in psoriasis  skin lesions
60,65,68
. There  is an intense 
cross-talk between cells of immune system and keratinocytes that 
establishes  an interactive cytokine heirachy,which is  responsible for the 
development of psoriasis. 
ROLE OF T CELL AND T CELL ACTIVATION 
   In  the early  skin lesions of psoriasis , the dermis is predominantly 
infiltrated by CD4
 
+  T helper  type of  cells, that  produces  interferon 
gamma and Interleukin -17, but not Interleukin - 4 or IL-10
66,69-71
. 
Therapy with systemic drugs  with cyclosporine A results in impairment 
of  cytokine production and T lymphocytes activation , and this  improves 
psoriasis 
72
. The importance of  role of T cells which promotes  psoriasis  
is substantiated by clinical observations from psoriatic patients with 
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haematological malignancy, who are cleared of disease  or obtained  
remission after bone marrow  transplantation  from healthy donor  
without  any  history of psoriasis
73
. Some of the  patients developed  
psoriatic skin lesions initially  after the bone marrow transplantation from 
donors suffering from psoriatic skin lesions
74
.   
Therapy for psoriatic lesions with monoclonal antibody targeted  
against  CD 4 molecules  improves skin lesion, whereas therapy  with 
monoclonal antibody  against the CD 8 molecules, does not improve 
psoriasis
75-77
. Also skin xenograft models on Severe Combined Immuno 
Deficiency mice shows that populations which includes autologous 
Interferon -γ- producing CD 4 T helper cells can produce  psoriatic skin 
lesions  in healthy grafts from patients with  psoriatic skin lesion  but 
autologous  transfer of CD8
 
 T helper  cells from  same patients with 
history psoriasis  could not induce the disease
78
. IFN-γ-producing Th1 
cells and IL-17-producing Th 17 cell plays pivotal role  for causing 
psoriasis
67,71,79,80
 . The   expression of  both  the Th17 cell promoting 
cytokine Interleukin 23 and the cytokine IL-22 which is  associated with  
Th17 cell in psoriatic skin,  supports that both Th1cell and Th 17 cell are 
responsible for  the manifestation of  psoriatic skin lesions
71,81,82
.   
                          Thus psoriasis is a Th 1cell /Th17 cell mediated 
autoimmune inflammatory condition. For the sustained  inflammation in 
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psoriatic skin lesion, the disease  inducing Th1 cells and/or Th17 cells 
either proliferates in situ  or migrates to  dermis – the  target organ from 
the peripheral site . The process  also depends upon close interaction  
between the inflammatory Thelper 1/Thelper 17 cells within the  dermal 
microvascular bed. There is an  interaction  between the lymphocyte 
function associated antigen - LFA-1 on  the lymphocytes and  the 
intercellular adhesion molecule - ICAM-1 on the endothelial cell which 
mediates  adhesion of  leukocytes to the endothelial cell  which is 
supposed to be prerequisite for extravasation of leucocytes. In 
inflammatory diseases, ICAM-1 is markedly   expressed on the 
endothelial cells of vascular structures. 
                         One school of thought is that there is abnormal regulation 
of T lymphocyte  and  also  interaction  between  the epidermal cells and  
an array of  cytokines  are  involved  in  pathogenic basis of 
psoriasis.
83,84.
 When the primary defect is  in  epidermal 
keratinocytes,injury in any form  either chemical or physical  damage to 
the defective keratinocytes  induces the production of cytokines followed 
by release of cytokines which results in antigen  independent  activation 
of  the T lymphocyte . This activation  leads to release of various other 
cytokines which is  followed by epidermal keratinocyte  proliferation, T 
lymphocyte  infiltration and  then inflammation.  
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Studies  by  Chang et al 
85
  demonstrates that the  cytokines 
secreted by  keratinocytes of  psoriasis  increases  activation of T 
lymphocyte to a significant level than the  cytokines secreted from  
keratinocytes of normal skin. One school of thought is  that only 
keratinocytes of psoriasis  skin lesions  respond to information from 
activated T lymphocyte  with hyperproliferation, because of their specific 
type of receptors or specific  signal transduction mechanisms
84
.
 
   
  Several studies shows that there is alteration in basement 
membrane  structures  and a heirachy of  cytokines  especially Thelper 1 
type  were involved in different stages of pathogenesis of 
psoriasis.
83,86,87.
   
 
ANGIOGENESIS 
Angiogenesis in psoriasis is a  cofactor as well as  induces 
development of psoriasis . Several changes in the  superficial 
microvessels  in psoriatic skin lesions results in an angiogenic phenotype. 
Proangiogenic cytokines like tumor necrosis factor, VEGF , hypoxia 
inducible factor , Interleukin 8 and angiopoietins, are increased  in  
lesional skin of psoriasis 
88,89
. A pro-angiogenic role is  related  to the T 
helper 17 cell-  cytokine interleukin 17
90,91
.  Angiogenesis is  balanced by 
interaction  between proangiogenic  stimuli and antiangiogenic stimuli 
and the expression of anti angiogenic factor expression is modulated 
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during development of  psoriasis. The epidermal keratinocytes isolated 
from psoriasis skin lesions  shows decreased expression of 
thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis. 
Thrombospondin inhibits endothelial Cell migration and proliferation, 
new vessel formation  and proliferation of  tumour cells
92,93,94
. In  normal 
healthy skin, production of thrombospondin -1  by basal epidermal cells 
maintains  the separation between the avascular epidermis and  vascular 
dermis
95,96
.   
These findings put together  suggests that the  involvement of 
angiogenesis in pathogenesis of psoriasis.  Physiological angiogenesis is  
seen transiently during  healing of wounds, pregnancy or the menstrual 
cycle. Pathological angiogenesis is seen in conditions like neoplastic 
growth of tumour  and chronic inflammatory conditions, which are seen 
in diseases like rheumatoid arthritis or psoriasis
89,97-100
.  
  Keratinocyte is one of the maximum source of proangiogenic 
cytokines such as vascular endothelial growth factor, interleukin  8 ,but 
actual mechanism of  angiogenesis in psoriasis is  not yet known. In the 
lesional skin of  psoriasis vulgaris , endothelial cells become swollen and 
gets activated which shows enlarged   Golgi bodies  and Weibel Palade 
bodies.
101
Activated endothelial cell  migrates, sprouts , and lays  a 
basement membrane with pericytes which is a structural support to form a 
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neo vascular structure.
 102
 Activated  and swollen   endothelial cells leads 
to widened  inter-cellular spaces and dilatation of dermal blood 
capillaries. 
The lesional skin capillaries adopts  a venous type, which includes 
bridging of  fenestrations, and expression of  E selectin, this helps for 
easier migration of leucocytes into the epidermis and dermis.
 88
  
DEFINITION OF ANGIOGENESIS  
 
Angiogenesis means new vessel formation from the  preexisting  
blood capillaries. It is seen during embryogenesis  whereas it  is absent  in 
many  of the  adult tissues. Angiogenesis takes place  in  two different 
manners : (a) the sprouting type – in which newer blood vessels sprouts 
from preexisting blood  capillaries and (b) the non sprouting type 
angiogenesis or also known as intussusception,in which there is  division 
of preexisting capillaries by trans-capillary pillars
103,104
. 
SPROUTING OF NEW VESSELS 
Sprouting type of angiogenesis is initiated by the activation of 
vascular endothelial cells through  various  factors  like vascular 
endothelial growth factor or basic fibroblast growth factor . The 
following are the  steps of angiogenesis   
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• Dilatation of blood vessels  
• increased vascular permeability 
• destabilization of  blood capillaries already existing,  
• degradation of the extracellular matrix  
• Endothelial Cell migration and proliferation 
• Formation of vascular lumen and maturation of vessels by 
recruitment of peri-vascular supporting cells
105,106
.  
 
Increased vascular permeability results in leaking of  plasma proteins  
that  provides a temporary matrix for migration of  endothelial Cells , also 
it requires the destruction of the extracellular matrix  by protease 
enzymes like matrix metallo-proteinases  and plasminogen activators. 
This  also  requires temporary destabilization of blood capillaries  by 
dissolution of  inter-endothelial and peri-endothelial cell contacts. Extra 
Cellular Matrix degradation  results in  release of proangiogenic factors  
vascular endothelial growth factor, insulin-like growth factor and basic 
fibroblast growth factor and are  stored in the extracellular matrix and 
hence  promotes angiogenesis.  
                 The migration of  endothelial cell  is guided  by the amount  of 
angiogenic cytokines, which  includes  the expression of integrins, 
cellular adhesion molecules on the endothelial cell surface, and  interacts 
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with extracellular matrix components. This newly formed  immature 
vascular   structures  acquires a vascular lumen and matures  by the 
recruiting the  supporting cells  like pericytes or the smooth muscle cell. 
In a mature and stable blood vessel,  the endothelial cells can survive for 
many years. 
MICROVESSEL CHANGES IN PAPILLARY DERMIS IN 
PSORIASIS  
 Psoriasis  skin lesions begins with neoangiogenesis in  superficial 
dermis. Dermal papillary capillaries shows prominent dilatation, 
increased  tortuosity,  permeability, and also shows elongation which is 
prominent.
107-109
.These morphological changes occur before  epidermal 
hyperplasia becomes evident
107,110
.The microvascular changes in early 
stages of  psoriatic lesions   correlates with increased cutaneous vascular 
flow  also in the neighbouring perilesional areas
111
.  Electron Microscopy 
reveals  ultrastructural changes in the capillaries  in the dermis.  
In normal skin, capillaries show  an arterial type,  whereas  
psoriatic plaques  exhibit characteristic features of venous type like  
single or multilayered basement membrane  with bridging of  
fenestrations in the endothelium
112
. Venous  capillary loops  returns to 
arterial capillary  loop  after therapy
112
. Normalization of the superficial  
dermal vasculature and capillary loops is followed by  normalization of  
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epidermis
109
. Apart from the morphological changes, the dermal 
microvasculature  in psoriatic skin shows an enhanced expression of 
inflammatory  associated adhesion molecules such as E-selectin, 
intercellular adhesion molecule 1 and vascular cell adhesion molecule 1.    
The  adhesion molecules allows firm binding of leukocytes to the 
endothelial cell 
113
, which is of prime importance for lymphocyte 
extravasation and inflammatory response. Migration and proliferation of 
endothelial cells  seem to be  important characteristic features of 
angiogenic  endothelial Cells. Endothelial cells show increased 
proliferation in psoriatic plaques
109,114 
proved by autoradiography and 
immunohistochemistry 
115
. For migration endothelial cells utilizes 
temporary adhesion  to constituents of the extracellularmatrix, and is 
mediated by  the integrins which are  present on the surface of endothelial 
cells.  
The Integrins are heterodimeric type of transmembrane proteins 
and it activates  intracellular signalling cascades  on adhering to the 
corresponding ligands. Many of the  integrins modulates the 
proangiogenic responses 
116
. Among these  type of  integrins, αVβ3 is 
expressed at  lower levels on inactive and quiet vessels. The αVβ3 integrin 
functions as endothelial cell receptor for von Willebrand factor(vWFr), 
fibrinogen and fibronectin
117
. In  angiogenesis, endothelial cell αVβ3 
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expression is markedly increased which may be  due to inflammatory 
conditions or from  neoplastic tumour growth.
98,99,118-119
. The supression 
of angiogenesis in vivo by peptides or monoclonal antibody antagonists of 
αVβ3 and this indicates its important role in neovascularization
118,119
. In  
psoriasis, enhanced  αVβ3 expression on endothelial cell  is noted.  The  
superficial microvessels of   psoriasis skin lesions  show  increased  αVβ3 
levels compared with healthy normal  skin
120,121
  Angiogenesis could be a 
reason for the proliferation of the superficial dermal microvessels  in 
psoriatic skin lesions. 
PROANGIOGENIC FACTORS IN PSORIASIS 
Angiogenesis  appears to be one of the prime factors of psoriatic 
skin lesion , several research works focuses on identifying the 
proangiogenic cytokines  in psoriasis  skin lesions. Evidence for 
keratinocytes producing  proangiogenic signals comes from an 
observation  that  compared the angiogenic  property  of conditioned 
media  from epidermal  keratinocytes obtained  from either psoriasis skin  
lesion   or non lesional skin of psoriasis patients
122
. Conditioned Media 
from psoriasis skin lesions or non lesional epidermal keratinocyte , 
activated and enhanced the endothelial cell migration in vitro which 
revealed strong neoangiogenic activity in  in vivo. Whereas  Conditioned 
Media from epidermal keratinocytes  of  healthy donor skin revealed  no 
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proangiogenic response. There is a large array of proangiogenic factors, 
which includes  vascular endothelial growth factor, hypoxia inducible 
factor, angiopoietin, Tumor necrosis factor alpha, Transforming growth 
factor α, Interleukin 8 and interleukin 17 . 
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
Vascular endothelial growth factor and their high affinity tyrosine 
kinase receptor  vascular endothelial growth factor receptor -1 and- 2 are 
primarily involved in vessel embryogenesis and adult new vessel 
formation. VEGF was initially  known as vascular permeability factor 
123.
 
. The  active form is a homodimeric type of  glycoprotein.  VEGFR 1 and 
VEGFR 2 are  expressed  by  endothelial cell. Vascular endothelial 
growth factor  binding to VEGFR 1 or 2 receptors results in activation of 
receptors and intracellular signal transduction
124-126
. Vascular endothelial 
growth factor  induced cell proliferation, survival, migration, and 
increased vascular permeability are essentially transduced by vascular 
endothelial growth factor receptor 2
127
. 
 
VEGF induced angiogenesis contributes to the pathomechanism of 
psoriatic skin lesions. In situ  hybridization and immunohistochemical 
studies reveals that a strong  upregulation of  vascular endothelial growth 
factor mRNA and expression of proteins  in  the cells of epidermis with  
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increased  expression of VEGFR 1 and VEGFR 2 on endothelial cells 
present in the dermis 
128
. As Transforming growth factor α induces 
secretion and expression of vascular endothelial growth factor by 
epidermal cells in vitro
130
 and is overexpressed  by  suprabasal  epidermal 
cells  of psoriasis skin lesions, transforming growth factor α may be a 
reason for the up-regulation of epidermal VEGF in psoriasis skin lesions. 
Serum  from patients with psoriatic skin lesions  showed  increased 
vascular endothelial growth factor levels. Also  serum vascular 
endothelial growth factor  levels  correlates  with disease severity
129-131
. 
Also  single nucleotide polymorphisms of  the vascular endothelial 
growth factor  gene correlates  with pathogenesis of psoriasis 
132,133 
and 
this suggests that VEGF represents a modified gene in the 
aetiopathogenesis of psoriatic skin lesions. 
The role of  vascular endothelial growth factor  in pathophysiology  
of psoriasis was tested using mice overexpressing vascular endothelial 
growth factor  in epidermis
134,135
 . Selective overexpression of VEGF  in 
basal keratinocytes  lead to a long standing  inflammatiory dermatological  
disease with increase in  number of dilated tortuous capillaries, 
expressing enhanced levels of VEGFR 1 and VEGFR 2, higher number of 
mast cells in the superficial  portion of the dermis and enhanced 
leukocyte rolling and adhesion
134
. Older K14VEGF animals 
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spontaneously developed an  skin lesion  with many features simulating  
psoriatic skin lesion  which includes inflammatory infiltrates of mixed 
population  of  CD 4
 
 T lymphocytes, macrophages, mast cells  and 
changes in the  microvasculature in the superficial dermis
135
. Transgenic 
mice treated with the vascular endothelial growth factor antagonist 
known as VEGF trap remained  healthy ,which supports the pivotal role 
involved by  VEGF in causing inflammatory skin  disease. 
Apart from its central  role which causes  aberrant angiogenesis in  
upper  portion of the dermis, vascular endothelial growth factor  also 
contributes to keratinocyte proliferation and  homeostasis of epidermal 
barrier
136,137
. Also  vascular endothelial growth factor receptor 1 and  2 
are detectable in  psoriasis skin lesions
136
. As VEGF induces increased  
expression of VEGFR  by keratinocytes in vitro and expression of  VEGF 
is upregulated by epidermal keratinocytes, and thus vascular endothelial 
growth factor  contributes to proliferation of keratinocyte  in an autocrine 
fashion. 
  Psoriasis can also be  aggaravated  by external injury  which is 
known as Koebner phenomenon and the damage to  the epidermal barrier 
homeostasis  stimulates  vascular endothelial growth factor expression
137
. 
Transgenic mice deficient in epidermal  expression of vascular 
endothelial growth factor  takes along for time permeability barrier to 
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recover , decreased density of dermal blood vessel  and  lacks  
keratinocyte hyperprloiferation and also angiogenic activity in response 
to  barrier disruption
137
. This elucidates the physiological production of  
vascular endothelial growth factor plays a role in normal  proliferation of 
epidermal keratinocytes, differentiation and functioning of the  normal 
epidermal keratinocytes. 
HYPOXIA INDUCIBLE FACTOR 
The cardio-vascular system is generally  needed for adequate 
oxygen supply  and nutrient supply. Thus  lower oxygen tension is an 
important trigger factor for angiogenesis. Hypoxia Inducible factor  
initiates  the basic  metabolic response to lowered levels of oxygen 
tension. Hypoxia inducible factor  also represents heterodimeric 
transcription factors consisting  of  β subunit - aryl hydrocarbon receptor 
nuclear translocator; and a regulatory al pha subunit (H I F 1α, H I F 2α, 
H I F 3α)
139-140
. At  normal  oxygen tension levels, the Hypoxia inducible 
factor α subunits are synthesized consistently  and destructed  by the 
proteasomes . For degradation, the prolyl  hydroxylases  hydroxylates  
prolyl residue of the hypoxia  inducible factor α subunit , that are active 
in the  normal physiological oxygen concentration level. The 
hydroxylated form of HIF  is  identified  by the Von Hippel Lindau  
tumour suppressor protein and leads to ubiquitinylation of hypoxia 
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inducible factor α and proteasomal destruction. Under hypoxia, prolyl 
hydroxylases are not active. So consequently, hypoxia inducible factor α 
subunit  is  not degraded and the increasing hypoxia inducible factor  
concentrations leads to  translocation in the nucleus. The  Hypoxia 
inducible factor  target genes that  regulates  angiogenesis are VEGF
141-
143
, VEGFR-1
144
 , VEGFR-2 
145
, IL-8
146
 and Tie-2
147
. 
In psoriasis skin lesions, HIF 1α and HIF 2α expressions are 
increased
148
. In epidermal keratinocytes, HIF 1α co locates with VEGF 
expression, whereas hypoxia inducible factor  2α is expressed in the 
epidermal keratinocytes and in dermal vasculature. Hypoxia of epidermis 
and enhanced hypoxia inducible factor expression could result from the 
robust keratinocyte proliferation and the increased  metabolic demands. 
Also   expression of Von Hippel Lindau mRNA and protein  are 
decreased
149
. 
ANGIOPOIETINS 
Apart from  the VEGFactor/VEGFactorReceptor  signal 
transduction system, the angiopoietin - Angiopoietin 1 and Angiopoietin 
2, and their receptor Tie-2, which is a  tyrosine kinase receptor, are all 
essentially  involved in angiogenisis . The Ang – Tie2 system is crucial  
for the growth, stabilization and maturation of blood vessels
150-152
. Ang-1 
induces Tie-2 phosphorylation  on adhesion  and  results in upregulation 
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of intracellular signal transduction pathways, which leads to stabilization 
of blood vessels and maintenance during vascular embryogenesis 
151
. In 
adults, the low level Tie 2 activation  maintains the  resting status of the   
endothelium
153
. In contrast, the Ang-2 antagonizes the activation of  Tie-2 
, this  causes vessel destabilization 
152
 and  sensitizes preexisting blood 
capillaries for survival and growth signals. If the  proangiogenic signals  
are absent , Ang 2  results in  vessel regression, whereas  in the presence 
of  proangiogenic stimuli Angiopoietin 2 results in angiogenic activity. 
The Ang–Tie-2 system is upregulated in  psoriatic skin 
lesions
154,155
. Angiopoietin 1 and 2 and Tie-2 are  increased in the  dermal 
connective tissue of psoriatic lesional skin
154
. Angiopoietin 1 is also 
expressed in fibroblasts, mononuclear cells or dendritic Cells, whereas 
angiopoietin 2 expression  appears  to be restricted to Endothelial Cell. 
The predominant  decrease  of  angiopoietin 2 expression following  
successful treatment  suggests  a central  role of  angiopoietin 2 during 
angiogenesis in psoriasis
154
. 
The pivotal contribution of signalling of Tie 2 to skin inflammation 
is demonstrated in a transgenic mouse 
155
. Overexpression  of Tie 2 
results in   inflammatory skin condition that  reflects  certain  
characteristics  features of  psoriasis like  epidermal keratinocyte  
hyperproliferation, hyperkeratosis, parakeratosis and inflammatory 
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infiltration  composed of lymphocyte, mast cells, macrophage and 
enhanced dermal vascularization. Repression of transgenic Tie 2 
expression  reversed the inflammatory skin lesion entirely. 
 Apart from the  role in angiogenesis, angiopoietin 2 also sensitizes 
endothelial Cell to these inflammatory signalling cascades  like tumor 
necrosis factor alpha by influencing TNF induced expression of  adhesion 
molecules like intercellular adhesion molecule 1 and vascular cell 
adhesion molecule 1 on endothelial cells  in an autocrine manner, hence 
facilitates  adhesion of leucocytes as well as leucocyte infiltration
156
. 
Thus, Ang-2 contributes to the inflammatory reaction in the development 
of psoriatic skin lesion. 
CYTOKINES 
Many cytokines creates a marked effect on angiogenic activity  and 
influences endothelial  cell  proliferation , survival and migration or  
modulates  the expression of proangiogenic factors or antiangiogenic 
mediators. Among the cytokines with proangiogenic activity, tumor 
necrosis factor , Interleukin-8 and Interleukin 17 are expressed in skin of  
psoriatic lesions . 
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TUMOUR NECROSIS FACTOR (TNF) 
TNF is the first member of the tumor necrosis factor  cytokines 
family and it  is produced  as a transmembrane precursor protein. TNF  is 
cleaved proteolytically into a soluble type of protein. It stimulates  
intracellular signalling by either adhering  to p55 tumor necrosis factor  
receptor  with  ubiquitous  type  of  expression  or p75 tumor necrosis 
factor  receptor  2 with a constrained type of  expression   by cells of 
immune sytem  and endothelial Cell. Tumor necrosis factor   results in   
endothelial cell activation  and it results in an enhanced expression  of   
the adhesion molecules and chemokines
157
. The impact of tumor necrosis 
factor on angiogenic activity is dose dependent and  also time reliant. It is 
also   influenced by  other tumor necrosis factor dependent mediators  
like  vascular endothelial growth factor  or platelet activating factor
157-159  
TNF stimulates  ceratin  proangiogenic mediators, such as vascular 
endothelial growth factor , interleukin-8 and basic fiboblast growth factor  
in endothelial cell
160
 and these factors exerts both proangiogenic  as well 
as  antiangiogenic effects. Tumor necrosis factor  was proved to inhibit  
endothelial cell  proliferation in vitro initially, but it  also causes new 
vessel formation in in vivo studies in  the rabbit cornea micropocket 
assay 
161
. TNF can be secreted by any type of  cells. Mast cell  stores  
preformed tumor necrosis factor, that is released in a rapid manner on 
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appropriate stimulation. Consequently  increased  levels tumor necrosis 
factor  mRNA and its  protein could be detected in psoriatic  skin lesions 
162
. Therapies  that  blocks the activity of tumor necrosis factor  leads  to 
clinical improvement of  psoriatic skin lesions and  also  decrease in 
expression of  the proangiogenic factors. Thus tumor necrosis factor  
takes part in angiogenesis which is  associated with psoriatic skin lesions 
. It is still debatable whether TNF causes angiogenesis directly  or 
indirectly through the stimulation of   proinflammatory cytokines or 
angiogenic factors. 
INTERLEUKIN 8(IL-8) 
 Interleukin 8 was  isolated  firstly  from the scales of psoriasis
68
. 
Interleukin 8 or CXCL8 belongs to a group of chemokines - CXC, that  is 
characterized by four cysteins which is highly conserved with  first 2 
cysteins separated by a nonconserved amino acid - CXC
163-165
. Interleukin 
8 is  a potential chemo attractant factor  for neutrophils, Tlymphocyte and  
basophils. It  is also plays a role in several auto immune diseases, 
inflammation  and infections
165
. Interleukin 8 is stimulated by  by 
Interleukin-1, TNF, Interleukin-6, Interferon -γ, lipopolysaccharide, 
reactive oxygen species and othercellular mediators . Interleukin-8 is  a 
strong  proangiogenic factor. The proangiogenic properties of interleukin 
-8 are independent  of  its proinflammatory functions, as interleukin-8 can 
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as well stimulate angiogenesis even when the  inflammation is 
absent
167,168
. Interleukin -8 has also  been shown to stimulate endothelial 
Cell proliferation,  survival ,migration and expression of  matrix metallo 
proteinases. Therefore, Interleukin-8 was shown to promote endothelial 
cell migration and endothelial cell  proliferation and tube formation of 
endothelial cell  in vitro
166,169,170
. Also, Interleukin -8 promotes 
endothelial cell survival by the inhibiting  apoptosis of EC  by inducing  
antiapoptotic proteins  and down regulation of  pro apoptotic proteins like 
Bax in endothelial cells 
170
. It can induce the   activity of matrix metallo 
proteinases 2 and 9. The in vitro studies  demonstrates  proangiogenic  
properties  of interleukin-8 and   established  by various in vivo         
assays
166-168
. 
Several  type of cells produce  interleukin -8, which includes  
immune cells  like  mast cells , neutrophils or T cells
171
, keratinocytes 
122
 
and EC
172
. Consequently  interleukin -8 is upregulated in psoriasis skin 
and downregulated after successful treatment
70
. Increased  interleukin-8 
and its  receptor mRNA can be demonstrated within the epidermis of 
psoriasis  skin lesions. Immunohistochemistry can localize Interleukin 8 
protein to suprabasal keratinocytes and neutrophils
171,173,174
. As 
interleukin-8  stimulates proliferation of  keratinocyte
 175
 and  thus IL-8 
stimulates the majority of  cell types in psoriasis. 
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INTERLEUKIN 17(IL-17) 
                       The proinflammatory cytokine interleukin 17 was termed 
formerly  as cytotoxic T lymphocyte  associated antigen 8 and  now 
known as interleukin -17 A 
176
. The  Interleukin-17 cytokine is in a family  
of six members, interleukin-17A to F, which plays a role in inflammation 
and autoimmune diseases like psoriasis and cancer
177
. IL-17A also 
stimulates the secretion of chemokines, various growth factors and  
several adhesion molecules by epithelial cells, fibroblast and endothelial 
cells, which includes  Interleukin-6, Interleukin-8, Interleukin-1, GM-
CSF, G-CSF, and intercellular adhesion molecule 1. Therefore, 
interleukin-17 potentiates  accumulation of neutrophils as well as  
granulopoiesis. Also , Interleukin -17A triggers the expression of tumor 
necrosis factor  and interleukin 1β by the  macrophages 
178
. The 
stimulation and production of Interleukin -17A during CD 4  or CD 8
 
memory T cell differentiation is regulated by an array of intimately 
related cytokines, which includes Transforming growth factor β, 
Interleukin-6, Interleukin 21 and Interleukin -23. 
IL-17A is a proangiogenic factor
91
. It can induce 
neovascularisation in the rat cornea  micro pocket assays. Interleukin 17A 
over-expressing tumour cells induces  a  swift neoplastic  growth with a 
significant increased tumour neovascularization in vivo
91
. In vitro, IL-
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17A  stimulates endothelial cell  migration and cord formation. 
Interleukin 17A induces  expression of  proangiogenic mediators, which 
includes vascular endothelial growth factor  that is responsible for the 
proangiogenic effects of Interleukin-17A. 
Though  an array of   cytokines was  found to be involved in 
pathomechanism  of psoriasis, but these cytokines alone cannot  be 
considered causing  psoriasis.
179
  The key cytokines involved in the 
pathobiology of psoriatic skin lesions are: 
TUMOR NECROSIS FACTOR ALPHA-  causes  stimulation of  
epidermal keratinocytes to produce ICAM-1,IL-8, ,TGF  ALPHA, BETA 
Defensins, GM CSF and plasminogen activator inhibitor 2. Increase the  
capacity of macrophage to secrete proinflammatory cytokines. It also 
stimulates endothelial cell to secrete VEGF  and  increases keratinocyte  
proliferation. 
INTERFERON GAMMA – it induces intercellular adhesion 
molecule 1 expression on epidermal keratinocyte and vascular endothelial 
cell and thus influences the migration of lymphocytes into lesional skin. It 
also stimulates APC activity and TNF aipha release from phagocytes. 
GM-CSF – It increases keratinocyte proliferation, activation of 
neutrophils,stimulates migration and proliferation of endothelial cells 
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INTERLEUKIN-1 – induces expression of E SELECTIN,ICAM 
1,VCAM 1 on epidermal keratinocytes and expression of  keratinocyte 
growth factor and GM-CSF on fibroblasts which promotes keratinocyte 
proliferation and differentiation. 
INTERLEUKIN-2 – It is a growth factor and chemoattractant for T cells 
as well. It also stimulates NK cell activity and induces T cell cytotoxicity. 
INTERLEUKIN 6 –  increase the proliferation, activation and chemotaxis 
of T lymphocyte in dermis. Activation and proliferation of B 
lymphocytes and macrophages. 
INTERLEUKIN 8-  migration of Tcells and neutrophils to the epidermis. 
It also activates and helps in proliferation of Tlymphocytes  along with 
stimulation of angiogenesis 
INTERLEUKIN 12- stimulates type 1 Tcell maturation pathway 
EPIDERMAL GROWTH FACTOR family – increased EGF/TGF alpha 
receptors in psoriatic epidermis 
VASCULAR ENDOTHELIAL GROWTH FACTOR -  it is icreased in 
psoriasis and causes erythema. Plays a role in regulation of  vascular 
growth and vascular remodelling in psoriasis. It acts as alink between 
angiogenesis and inflammation in psoriasis. 
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NERVE GROWTH FACTOR- overexpressed in psoriasis. It  stimulates 
keratinocyte proliferation,endothelial cell proliferation and adhesion 
molecules expression. 
INTERLEUKIN 23-  It increases the levels of Interleukin-17 and 
Interleukin-22. It induces T helper17 cells and activates  nuclear STAT3 
transcription. It causes acanthosis and mixed inflammatory infiltration. 
INTERLEUKIN 22- In association with IL-17 ,it induces defensins,MMP 
and molecules like s100A7 which induces keratinocyte mobility. 
INTERLEUKIN- 17- increases the expression of ICAM-1 on fibroblast.   
    Recent studies has identified  a chemokine CX3C L1 known as 
Fractalkine in Psoriasis in human beings. CX3C L1 is produced in the 
form of  a lengthy  protein with 373-amino acid  with an extended mucin 
like stalk with a chemokine domain on the top. The mucin like stalk  
allows fractalkine to attach to the surface of  several types of  cells. But  a 
soluble form of this chemokine has  been demonstrated. Soluble form 
CX3C L1 strongly  chemoattracts T lymphocytes and monocyte, whereas 
the cellbound  form of chemokine enhances  adhesion of leukocyte  to the 
stimulated  ECs. Fractalkine binds to its seven trans-membrane domain G 
protein coupled receptor CX3C R1 and this binding induces  signalling 
and mediates cellular adhesion.
 180,181
 CX3C L1 is also expressed in 
several organs such as  brain, heart, kidney,heart, muscle,lung and testis 
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wherein  it interacts with a single G  Protein Coupled Receptor and 
CX3CR1  induces  chemotaxis and adherence  of CX3C R1 expressing 
cells which includes neutrophils, Th-1  cells,natural killer cells and 
monocytes.
 182
  
SUMMARY OF PATHOGENESIS  OF PSORIASIS 
The inflammatory infiltrate seems to be the prime reason for the 
whole pathogenesis of psoriasis. There is a significant correlation of 
epidermal hyperplasia with the inflammatory infiltrate, spongiform 
pustules of Kogoj, capillary proliferation and parakeratoses .  
Studies have shown that aberrant  regulation of T lymphocytes 
along with interaction between epidermal  keratinocytes and a composite 
array of cytokines are  involved in the pathomechanism of  psoriasis. An 
injury to these defective epidermal  keratinocytes results in activation of  
synthesis and release of  several cytokines. These cytokines  enhances  T 
lymphocyte activation.This leads to secretion of  several cytokines and 
various growth factors by the T cells, in addition to further proliferation 
of keratinocytes and thus  a vicious cycle of events. This cycle explains 
there is a significant correlation between the degree of epidermal 
hyperplasia and the inflammatory infiltrate. One school of thought is that                                                                       
neutrophils are recruited by the neutrophil-attracting chemokine 
interleukin-8 (CXCL8). IL 8 mRNA is can  be synthesized by the CD 4 
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subset of T cells. There appears to be a strong correlation between the 
inflammatory infiltrate and the grade of capillary proliferation and also a 
significant correlation between the epidermal hyperplasia and the grade 
of capillary proliferation .  It is also believed that Vascular Endothelial 
Growth Factor and IL -8 released from  epidermal keratinocytes  
contributes to the neovascularization  in psoriasis. Several studies  
suggests that lymphocytes  releases angiogenic factors  which  induces 
capillary proliferation and vasodilatation
7
. A series of  experiments by 
Mor et al., proved that T cells can synthesize and secrete 
VEGF
183
. Immune processes and inflammatory cascades are well known 
inducers of angiogenesis and also angiogenesis promotes and maintains 
immune responses and inflammatory cascades
98 
HISTOPATHOLOGICAL FEATURES OF PSORIASIS 
       Psoriasis is a dynamic process and hence the histopathological 
features varies during the evolution and subsequent resolution of 
individual lesions.  
EARLY LESIONS 
The earliest change, seen in lesions of less than 24 hours’ duration, 
consists of dilatation and congestion of blood vessels in thepapillary 
dermis with a mild, perivascular, lymphocytic infiltrate, and adjacent 
edema. There is also some exocytosis of lymphocytes into the epidermis 
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overlying the vessels and this is usually associated with mild spongiosis . 
The epidermis is  normal. This is soon followed by the formation of 
mounds of parakeratosis, with migration of neutrophils through the 
epidermis to reach the peaks of  these parakeratotic . There is  overlying 
orthokeratosisof normal basket-weave type and loss of the underlying 
granular layer
4
. 
PAPULAR LESIONS 
At the papular  stage, there is increased mitotic activity can be seen 
in the basal layer of the epidermis associated with a psoriasiform 
acanthosis . Keratinocytes in the upper epidermis shows cytoplasmic 
pallor. Blood vessels in the papillary dermis are dilated and somewhat 
tortuous, and their lumen might contain neutrophils. Lymphatic channels 
are also increased.  Few neutrophils are ever present in the perivascular 
infiltrate: this consists  of lymphocytes,  Langerhans cells, and 
indeterminate cells. A few extravasated erythrocytes may also be seen. 
These changes are also  seen in guttate psoriasis although the mild 
epidermal hyperplasia is usually seen in this variant of psoriasis. 
PLAQUE LESIONS (EARLY AND LATE LESIONS) 
In early plaques of psoriasis and in ‘hot spots’ of  established    
plaques lesions, there is of parakeratosis containing neutrophils, which  
migrates to the upper layers  of  mounds of parakeratosis. With time, 
confluent parakeratosis is seen . Several layers of parakeratosis  
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containing neutrophils, with intervening layers of orthokeratosis, are  
present.  Intracorneal  collections  of neutrophils  known as  Munro 
microabscesses are common, similar collections in the spinous layer 
known  as spongiform pustules of Kogoj are less common. They are also 
much smaller than in pustular psoriasis
4
. These pustules contain 
lymphocytes in addition to neutrophils. The epidermis   shows 
psoriasiform (regular) hyperplasia, with  suprapapillary plate thinning  
overlying the dilated vessels of the papillary  dermis . Increased  
expression  of Ki 67 is noted . A few mononuclear  cells are usually 
present in the lower layers of the suprapapillary epidermis. 
           The dermal inflammatory cell infiltrate is usually a  heavier than in 
earlier lesions. The dermal inflammatory infiltrate includes  activated T 
lymphocytes fewer  Langerhans cells  as compared to earlier lesions, and  
occasional neutrophils. A subset of spindle-shaped macrophages are  
situated along the basement membrane, and it is  described as a 
characteristic feature. 
They are known as ‘lining cells’ that are positive for CD11c
4
. 
Plasma cells and eosinophils are usually absent,   but eosinophil cationic 
protein is  identified, particularly in the upper third of the epidermis in 
psoriastic lesions.  
Plasma cells may be present in patients with HIV  infection.With 
time, there is club-shaped thickening of the lower rete pegs with 
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coalescence of rete pegs in some areas. Later lesion shows orthokeratosis, 
an intact granular layer, and  thickening of the suprapapillary plates. 
Migration  of inflammatory cells is usually mild. The finding of  many 
fatty vacuoles in the papillary dermis – pseudolipomatosis cutis  is of  
less significance. 
         Differentiation  of  late plaque  lesions of psoriasis from lichen 
simplex chronicus might be  difficult, but in contrast  in  lichen simplex 
chronicus  , the suprapapillary  plates and granular layer are  more 
prominent and  vertically oriented collagen bundles are seen  in the  
dermis.  The histopathological features of  the  psoriasis  lesions  may be 
obscured by  superimposed changes due to rubbing or scratching 
PSORIATIC NEURODERMATITIS 
           The terminology  psoriatic neurodermatitis  is used for pruritic, 
lichenified plaques  seen on the elbows and/or knees
4
. Lesions are 
numerous in number, smaller in size , more keratotic, and less excoriated 
than  lichen simplex chronicus. 
HISTOPATHOLOGY OF  PSORIATIC NEURODERMATITIS 
Microscopically the lesions show  microabscesses in the horny cell  
layer,  regular acanthosis, hypogranulosis and  suprapapillary plates 
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thinning in epidermis. One school of  thought  is that these cases 
represent psoriasis with superimposed lichen simplex chronicus. 
TREATED  PLAQUE  LESIONS OF PSORIASIS 
In resolving or treated plaques of psoriasis there is a marked  
decrease in the inflammatory infiltrate, a decrease  in the amount of 
hyperproliferation  of epidermal keratinocytes, and normalisation of the 
granular  cell layer. Vessels in the papillary dermis are  dilated, albeit by 
this stage there is an increase in  number of fibroblasts in this region with 
only mild fibrosis. After a period of  10–14 weeks of treatment , the 
histological appearances return to normal. 
HISTOPATHOLOGICAL CHANGES IN SCALP REGION 
Changes   reported in psoriasis of the scalp are minor changes only 
and  includes  sebaceous gland atrophy, a decrease in  size of  hair follicle 
and thinner hair shafts. Other features of scalp psoriasis includes  
infundibula dilatation with parakeratosis at the lips of the ostium of 
infundibula, papillomatosis, and scattered apoptotic keratinocytes. Munro 
microabscesses are  not common in this region. 
Regional variations includes  reduced epidermal hyperplasia seen 
in psoriatic lesions  of  the penis and vulva; spongiosis may be present. 
           Spongiosis is  a feature of the early  lesions of psoriasis, and of 
psoriasis occurring in various regions such as the hands and feet and 
genital regions. It may also occur in erythrodermic  psoriasis . The 
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terminology spongiotic psoriasis is given for  those cases with significant 
spongiosis in early stages , but  with  time  evolves  into classic psoriasis. 
The  initial biopsies show  spongiosis, mounds of parakeratosis 
containing neutrophils, dilated vessels in the papillary dermis, and a mild, 
superficial perivascular infiltrate of lymphocytes.  
NAIL CHANGES IN PSORIASIS 
            The nail plate in nail lesions of  psoriasis shows hyperkeratosis, 
focal  parakeratosis, and variable number of  neutrophil exocytosis into 
the parakeratotic layer. Spongiosis is one of the common features of nail 
psoriasis. Examination of periodic acid Schiff ‘s stained  sections is 
required  before making a diagnosis of nail psoriasis  because of its 
similar histological features to onychomycosis. 
 
HISTOPATHOLOGIC  FEATURES OF ERYTHRODERMIC 
PSORIASIS 
The histopathologic  of erythrodermic psoriasis  appearances  
resembles those  seen in early lesions of psoriasis, possibly a reflection of 
the early medical treatment that  is usually given  in this condition. 
Dilated  superficial vessels is usually  prominent. A cornified layer is 
absent. Sometimes the histological features  might  not resemble those of 
psoriasis at all. 
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HISTOPATHOLOGICAL FEATURES OF FOLLICULAR 
PSORIASIS 
                  The histopathological features in follicular psoriasis are 
follicular plugging with marked parakeratosis in the mid-zone of the 
ostium. Both perivascular and perifollicular  dermal inflammatory 
infiltrate is noted. 
 
HISTOPATHOLOGICAL FEATURES OF ANNULAR 
VERRUCOUS PSORIASIS 
The features are  exaggerated papillomatosis resulting in finger-
like projections of the epidermis. The papillomatosis and bowing of the 
peripheral rete ridges toward the center of the psoriatic lesion mimics the 
appearance of verruca vulgaris. 
 
HISTOPATHOLOGY OF GENERALISED  PUSTULAR 
PSORIASIS 
Macro Spongiform pustules of kogoj are seen in all types of  
variants of generalised  pustular  psoriasis  and it is representative of 
characteristic histopathological  lesion. The spongiform pustular  is 
formed due to migration and accumulation of neutrophils from papillary 
dermal vessels  to the uppermost  layers of epidermis. The neutrophils 
accumulates within the interstitium of sponge like network formed by 
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degenerated and degraded epidermal keratinocyte. In a large pustule, the 
epidermal keratinocyte in the middle of the lesion undergoes cytological 
destruction  resulting in formation of a large cavity, however in the 
periphery of the lesion the thinned out epidermis persists. When  the 
neutrophils in the pustular lesion migrates up into the horny layer, they 
become pyknotic forming  a large munro abscess. Other features are 
parakeratosis, elongation of rete ridges. Dermis reveals lymphocytic 
infiltrate
4
. 
HISTOPATHOLOGY OF LOCALISED PUSTULAR TYPE OF  
PSORIASIS 
Early lesion shows  spongiosis and extravasation  of lymphocytes 
in the lower epidermis overlying papillae of dermis. This is followed by 
formation of small intra epidermal vesicle which contains only 
lymphocytes . There  is massive extravasation of neutrophils which 
penetrates the intercellular spaces in the wall of the vesicular lesion, 
forming spongiform pustules. In the acute type, pustular bacterid, 
leukocytoclastic vasculitis is noted.  
DIFFERENTIAL DIAGNOSIS OF PSORIASIS 
1.  Mycosis  fungoides or cutaneous Tcell lymphoma 
2. Pityriasis rosea 
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3. Nummular dermatitis 
4. Pityriasis lichenoides chronica 
5. Pityriasis rubra pilaris  
6. Secondary syphilis 
7. Bowen’s disease 
8. Acute generalized exanthematous pustulosis 
9. Hypertrophic lichen planus  
10. Sneddon–Wilkinson disease 
11. Small plaque parapsoriasis 
12. Intertrigo 
13. Langerhans cell histiocytosis 
14. Dyshidrotic dermatitis 
15. Tinea manuum/pedum/capitis  
16. Seborrheic dermatitis 
 
Chronic plaque type of psoriasis should  be differentiated  from  
mycosis fungoides type of cutaneous T cell lymphoma. Mycosis 
fungoides shows signs of atrophy of epidermis  or poikiloderma which is 
a differentiating feature from plaque type  psoriasis; but a  biopsy of skin 
is  required to differentiate  between the two
184
. 
Pityriasis rubra pilaris- PRP is differentiated  from plaque type  
psoriasis clinically by the occurrence of reddish-orange palm plantar 
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keratoderma, keratotic follicular papules  and  classically spares  the 
trunk. Histopathologic features are alternate horizontal , vertical 
orthokeratosis and parakeratosis with follicular plugging  that helps to 
differentiates PRP from psoriasis.  
Bowen’s disease and Nummular dermatitis  are  differential 
diagnosis of plaque type  psoriatic lesions. 
       Nummular dermatitis is more pruritic than psoriasis and  linked 
to   previous  history of atopy. Histological study is more dependable   to 
distinguish nummular dermatitis from psoriasis plaque and Bowen’s 
disease. If  psoriasis occurs in  the tibial shin,  hypertrophic lichen planus 
should be thought of, however  a typical lichen planus lesion occurs  
elsewhere  on the body in addition to involvement of mucosa  helps to 
distinguish  between the two
184
.  
Guttate psoriasis can be diagnosed in a staright forward manner, 
but the differential diagnosis includes small plaque type para-psoriasis, 
pityriasis rosea, secondary syphilis  and pityriasis lichenoides chronica 
clinically.These entities should be differentiated from guttate psoriasis 
based on  history , clinical findings , histopathologic features, and 
laboratory values.  
52 
 
Small plaque type  parapsoriasis presents with various types of   
erythematous  plaques and roofed by  fine scales.Infrequently, it might 
present with lengthened, finger like  patches  that are symmetrically 
dispersed on the flanks, and it is called as “digitate dermatosis.”  
Pityriasis rosea is differentiated from psoriasis by the presence of  
herald patch and remission of the disease in a duration of  few months. 
Secondary syphilis should  be clinically differentiated based on 
palmoplantar involvement, that  is not seen in guttate psoriasis, and on 
the basis of histopathological features and serological studies. 
Pityriasis lichenoides chonica  is  characterized  by clinical 
appearance  of  recurring crops  of spontaneously regressing,  reddish-
brown papules with scales. Histopathologically, there is an interface 
dermatitis consisting  of monoclonal T lymphocytic population 
predominantly and keratinocytes which are necrotic
184
.  
Pustular psoriasis  resembles  a  pustule  type of  drug reactions, 
similar to acute generalized exanthematous pustulosis, 
SneddonWilkinson disease and  Ig A  pemphigus. The presence of 
peripheral eosinophilia and tissue eosinophilic infiltration on the 
histological section and  a previous history   medication intake  favors 
the diagnosis of acute generalised exanthematous pustulosis.  
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SneddonWilkinson disease can be clinically differentiated by its 
annular type of  plaques with  flexor surfaces being more prone for 
lesions. The diagnosis of Ig A pemphigus  can be given by using  direct 
immunofluorescence studies which is positive,and  is absent in both 
psoriatic skin lesion and SneddonWilkinson disease. The annular type of 
pustular psoriasis  mimics SneddonWilkinson disease.  
The important  differential diagnosis of  inverse  psoriasis includes 
intertrignous lesions and if infants- Langerhans cell histiocytosis(LCH) . 
Patients with LCH  can have scales and crusts on the scalp, as well as 
affecting internal organs  such as liver enlargement , lytic bony lesions. 
Histopathological examination of skin should be diagnostic.  
The differential diagnostic consideration for palmoplantar type of  
psoriasis includes dyshidrotic dermatitis and tinea manuum or pedum. 
Yellowishbrown macular lesions mixed with sterile pustular lesions 
favors  palmoplantar  type of psoriasis. The KOH preparation of  scales  
helps  to diagnose a dermatophytic infection
184
.  
Nail psoriasis  mimics lichen planus, alopecia areata or 
trachyonychia. Pitting of nails is a common feature for  both alopecia 
areata and  Psoriasis.  
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Nail pits are larger, deeper and  distributed in an irregular manner 
in psoriasis whereas in alopecia areata nail pits are smaller in size, 
superficial and distributed in a regular manner. Oil drops, splinter 
hemorrhages and distal onycholysis  helps to differentiate  between the 
two disorders.   Thinning  of nails laterally , linear ridges , fissures and 
dorsal pterygium are some of the features that favors the diagnosis of  
lichen planus. Trachyonychia or also known as twenty nail dystrophy 
can be owing to   psoriasis, alopecia areata, or lichen planus,. In case of  
lack of cutaneous features,  biopsy of nails helps to arrive at a diagnosis. 
Scalp psoriasis  resembles tinea capitis and seborrheic dermatitis.  
Psoriasis  could  be clinically differentiated from tinea capitis, laboratory 
tests  are required  to confirm the diagnosis of  dermatophytosis.  
Laboratory tests includes a KOH examination, microbiological  
culture studies for fungi  or  histopathological examination of a skin 
biopsy .  
Seborrheic dermatitis and psoriatic lesions on the scalp  presents 
clinically in a similar  manner and  responds to the similar  topical 
treatment. However  the  occurrence  of psoriatic plaque lesions on the 
trunk along with a positive family history of psoriasis  favors diagnosis 
of  psoriasis.  
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              Histopathological examination is  the gold  standard for  
distinguishing between seborrheic dermatitis and psoriasis. Lastly 
psoriatic erythroderma has a larger  differential diagnosis, and there are 
several  etiologies for  erythrodermic psoriatic lesions which includes 
seborrheic dermatitis, Sezary syndrome ,atopic dermatitis,pityriais rubra 
pilaris, drug reactions, and graft versus host disease. A skin biopsy  
establishes  the underlying etiology. Classic type of psoriatic plaques 
precedes psoriatic  erythroderma  but  typical psoriatic features  are lost 
when there is  development of  generalized erythema. Nail changes like  
pitting of nails , oil drop and  onycholysis might be seen  and provides a 
hint to the diagnosis of psoriasis erythroderma
184
.  
CLINICAL FEATURES OF PSORIASIS 
                Psoriasis is a papulosquamous disorder with varied 
morphologic features, different distribution , severity, and variable 
course. It classically presents as circular and well circumscribed 
erythematous papular lesions or plaque leions  with a greyish or 
silverywhite dry scales.  The  psoriatic lesions are  symmetrically 
dispersed on the scalp body fold region, elbow, knee and lumbosacral 
area,. Psoriasis can develops at the sites of physical damage or chemical 
damage which is  known as Koebner phenomenon.  Uncontrolled 
psoriasis leads to condition known as  generalised exfoliative 
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erythroderma.  Involvement of nails  can be present, especially when 
psoriatic arthritis  is present. 
Psoriatic lesions  might  occur in the  oral mucosal region or 
tongue. If it  involves  the dorsal surface of tongue , lesions will  have 
sharp circumscribed gyrate reddish  patch with a whitish yellow border. 
The patches might extend , changing on a regular basis, forms specific  
annular pattern and  resembles a map, so it known as  geographic tongue. 
Psoriasis has a varied morphologic features, distribution, and 
intensity . Albeit  the classic clinical  presentation as  above, the 
morphology can ranges from smaller  papules- guttate psoriasis to 
pustular lesions -pustular psoriasis  and generalised erythematous lesions 
with scaling – psoriatic erythroderma. Also  these different types of 
psoriasis might be limited to small area  or  generalised. Psoriasis has a 
varied course presenting as chronic plaque or  presents in an acute form 
that progresses rapidly  with widespread involvement
185
. Psoriasis can be 
symptomatic with  complaints of  severe itching  or burning sensation.  
Several studies in India have studied  the  varied clinical features  
of the clinical disease in psoriatic patients. Okhandiar et al.
186
 collected 
epidemiological data of 116 patients with psoriasis from several  medical 
institutions. They observed  that the extensor aspect (93%) is the more 
common site of  occurrence  followed by the scalp region  (88%). Face, 
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palms, soles and nails are also involved  in one third of the psoriasis 
patients. Flexural  psoriasis was not common. None of their patients had 
oral mucosa affected. 
 Bedi 
187
 analyzed data of 530 cases of  psoriasis for duration of 5 
years . Chronic plaque  psoriasis seemed to be the  more  common (90%) 
clinical presentation. The general sites  involved are in a descending order 
are trunk, limb, scalp region, face, palmar areas ,soles and flexural region. 
The second common clinical presentation is palmo plantar type of  
psoriasis followed by inverse  psoriasis. He also  found that guttate 
psoriasis, oral mucosa affection, and erythrodermic psoriasis are rare.                    
         Kaur et al. 
188
 found that scalp region  (25%) as the more common  
site of involvement followed by lower limbs (20.6%) and upper limbs 
(11.7%). Oral mucosal (0.7%) and genital (0.4%) mucosal involvement is 
not common. Chronic plaque psoriasis (93%) was the more  common 
clinical presentation. Palmo plantar pustular psoriasis , guttate psoriasis 
and erythrodermic  psoriasis accounted for less than 2% of cases  for each 
variant. Generalized pustular psoriasis, isolated nail psoriasis, flexural 
psoriasis  and  psoriatic arthritis were  not so common.   
The various clinical presentation of psoriasis are given below
185
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PLAQUE  TYPE OF PSORIASIS (PSORIASIS VULGARIS)
 
      The most common form of psoriasis is plaque type  psoriasis which 
presents as a well circumscribed, round to oval, or nummular  plaques . 
The lesions  first  begins as an erythematous flat  macules less than  one  
cm or papules, which spreads to the peripheral areas  and coalesces to 
result in  plaque lesions  of  1cm to many centimetres in diameter. A 
whitish blanched ring also  called  as Woronoff’s ring, is seen in the skin 
around  a psoriasis  plaque. With  further spread  of  lesions to the 
periphery , plaque  develops  different configurations  which includes: 
• psoriasis gyrate -  curved linear type  are seen predominantly 
• annular type of  psoriasis - ring like lesions that  develops  secondary  
      to central clearing 
• psoriasis follicularis -  minute scaly papules located at the opening of 
•  pilo-sebaceous  unit. 
The  rupioid type of psoriasis  and  the ostraceous type  refers to 
specific morphologic  subtypes of plaque type of  psoriasis.                      
• Rupioid  lesions  are smaller in size  with two to five centimetres  
in diameter and markedly  hyperkeratotic lesions  which resembles  
limpet shells.  
• Ostraceous  subtype  are  hyperkeratotic plaque  with a concave 
centre, simulating an  oyster shell.
185
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Scales are present in  plaque type of psoriasis, which  
characteristically has  silvery whitish appearance, and varies in thickness. 
Scraping  of scales   reveals  smaller  bleeding points  known as Auspitz 
sign. The quantity  of scales  vary  among different  patients and also  at 
different sites of  lesions  in the same  patient. The  acute  inflammatory 
or exanthematic psoriasis, scaling is  minimal and erythematous lesions  
might  be the prominent clinical feature. 
In   cutaneous involvement, plaque type of  psoriasis is associated 
with internal involvement, which includes joints and extraarticular sites 
like the eyes. Coexistent psoriatic  arthritis  is present  in  5%–30% of  
psoriatic patients .
189
 In a minority of patients, the features  of psoriatic 
arthritis appears before  affecting the   skin. The  classical  clinical  
manifestation  is  asymmetrical oligo-arthritis with involvement of the 
distal  and proximal  interphalangeal  joints of the hand and foot. Erosive 
change  occurs  years after the presenting peri-articular inflammation. 
The occurence of eye  involvement in patients with psoriasis is yet to be  
known; but occurs  in approximately 10% of psoriasis cases.
190
 Psoriasis 
can involve almost any part of the eye which results   blepharitis,  cataract 
formation, peripheral keratopathy, acute anterior uveitis, , conjunctivitis 
and posterior synechiae. 
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GUTTATE TYPE OF  PSORIASIS 
                    Guttate type of  psoriasis, comes from the Greek word gutta 
 which means a droplet, and it has  sudden  onset  of small,two to ten 
millimetre  diameter lesions of psoriasis. The  lesions  are  distributed in a 
centripetal manner  albeit guttate lesion  also involves  the head, arms and 
legs. Typically, the  guttate psoriasis  presents  following an  acute group 
beta  haemolytic streptococci  infection of the pharyngeal or tonsillar 
region  and might  be the first  clinical presentation of psoriasis in 
children or in adults which is rare. The number of  lesion  ranges from 
five or ten to hundred . Guttate psoriasis is accountable for  two percent  
of  the total number of  psoriasis cases. In children, the  acute form of  
guttate psoriasis  is  self limiting illness; whereas in adults, acute guttate 
form   complicates long standing  psoriatic plaques. A small  study  
showed  that 33% of patients with acute guttate psoriasis finally develop 
into chronic plaque psoriasis.
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INVERSE(FLEXURAL) PSORIASIS 
Psoriasis  which affects the flexural areas such as  inframammary 
region, perineal area, and axillary region, has  different morphological 
feature  when compared to  usual type of  plaques occurring somewhere 
else on the trunk ,upper limb and lower limb. Flexures with  plaques  do 
not have   scales  and appears  as reddish, shiny, well circumscribed 
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plaques sometimes confused with candida  intertrignous infection, and 
dermatophyte infection. 
ERYTHRODERMIC PSORIASIS 
Complete  or subtotal involvement of the skin by active psoriatic 
lesions  is called as erythrodermic psoriasis . First is that chronic plaque 
psoriasis  gradually progresses , that becomes  continous  and widespread. 
Second is that erythroderma might be a clinical  presentation  of unstable 
type of  psoriasis which is  triggered  by infections, tar, drug intake, or 
withdrawal of steroids. Erythroderma  affects  the temperature-regulatory 
efficiency of the skin which results in  decrease in body temprature, high 
output heart failure, and several  metabolic changes like  hypo-
albuminaemia, and severe anaemia due to loss of iron, vitamin B12 and 
folic acid. 
GENERALISED PUSTULAR TYPE OF PSORIASIS 
Generalised pustular type of  psoriasis -von Zumbusch  is very rare 
and it represents an unstable  active form of   psoriasis. Systemic or 
powerful  topical steroids and infection  precipitates this clinical subtype. 
The patient will have fever, with reddish, painful, inflammed skin 
studded with uniform looking, sterile pustular lesions, that  coalesces to 
form larger sheet of lesion. Patients with generalised pustular type of  
psoriasis   needs admission  in the hospital for further treatment. 
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PALMOPLANTAR  TYPE OF PUSTULOSIS 
Palmoplantar pustular lesion  manifests  as sterile, yellowish 
pustular lesions  on an erythematous background  with scaling , that  
affects  the palmar areas  and soles . The pustular lesions  are painful and 
fades away to form dark brownish colouration with  sticky  scales or 
crusts formation. Palmo plantar pustulosis also have  affected nails. 
Around  25% of patients  are  related to  classic type  psoriasis vulgaris, 
but it is  now thought  that palmoplantar pustulosis might  not be a type  
of psoritic  lesion.
192
 This assumption was derived from  genetic studies 
that showed no link with HLA-Cw6 or other genetic  markers  on 
chromosome 6p that  are associated  with  chronic plaque type psoriasis 
and guttate  type of psoriasis. The epidemiology of palmoplantar 
pustulosis is   entirely different from  chronic plaque type psoriasis in that 
it affects women most commonly  , mostly  presents in the age group of 
40 to  60 years, and has a  strong   association with smoking,  which may 
be either present  smoking  or past history of smoking, in  95% of 
patients.
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PSORIATIC NAIL DISEASE 
Finger nails are mostly  affected than  the toe nails. The common  
findings  are  tiny  pits in the nail plate, that results from deficient  nail 
formation in the proximal part  of the nail matrix . The nail   detaches  
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from the nail  bed at its distal attachment  or its  lateral attachment ,which 
is known  as onycholysis . Orangish yellow areas might  be seen  below  
the nail plate ares and are known   as “oil spots”.  The nail plate  becomes  
thickened , also  dystrophic and discolored nail plate is also noted. 
Yellowish  keratinous material might get collected beneath  the nail plate 
and it is termed  as subungual hyperkeratosis. 
OTHER  DISEASE ASSOCIATION WITH PSORIASIS 
Patients with psoriatic lesions  are at  risk of several other diseases 
due to sharing of  genetic pathway , similar immune cascades, therapy 
associated adverse effects and toxicities, and allied  psychological stress 
of the disease
184
.  
Psoriatic  patients have an higher incidence of inflammatory bowel 
disease specifically Crohn’s disease, that might be owing to sharing of  
genetic pathways. Other diseases associated are obesity, metabolic 
syndrome, type 11 diabetes, malignancy and psychological co – 
morbidities. Epidemiological studies shows that  patients with psoriatic 
skin lesions  have a increased risk of developing  specific  metabolic 
disorders like obesity. Mechanism  by which psoriasis  leads  to obesity 
has been suggested, includes higher incidence social isolation, unhealthy 
diet, increasing depression, intake of  alcohol  and decrease in  physical 
exercises. Few studies  demonstrates that a increased  occurrence of 
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diabetes in  psoriasis independent of  usual  risk factors for such as age, 
gender, obesity, hyperlipidemia and hypertension
184
.  
HIV associated psoriasis occurs with an  increased  occurence than 
in  general population. Psoriasis can also  present for the first time in a 
later stages of  retroviral  infection, when  the CD 4 cell count is less than 
100 cells/ microliter . Psoriasis  also  spontaneously improves in the  end-
stage AIDS
184
. 
 
. 
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MATERIALS AND METHODS 
STUDY DESIGN 
This is a case control study carried over a period of 15 months 
from  April 2013  to July 2014 in Coimbatore Medical College and 
Hospital. 
PATIENT SELECTION 
Thirty two psoriasis cases selected from Department of 
Dermatology in Coimbatore Medical College. Patients included are 
newly diagnosed psoriasis cases and patients did not receive any topical 
or systemic treatment for psoriasis for at least two months prior to the 
study. Skin biopsies are taken from psoriasis patients attending 
dermatology department in Coimbatore College From every patient, 
elliptical biopsy is taken from skin unexposed to sunlight involving 
lesional  skin. Controls were from skin such as circumcision of healthy 
persons and normal skin from other departments such as plastic surgery. 
Patients with psoriasis vulgaris are assessed for severity of lesions 
by a scoring system known as PASI score. It is based on lesions, area of 
distribution of lesions. Finally distribution of lesions for the entire whole 
body is calculated.    
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TABLE  - 1 
PASI SCORE- SEVERITY OF LESION 
INDURATION, 
ERYTHEMA, 
SCALING 
No 
symptoms 
Slight Moderate Marked 
Very 
marked 
SCORE 0 1 2 3 4 
 
 
TABLE - 2 
PASI SCORE –AREA OF DISTRIBUTION 
 
  
AREA 0 1-9% 10-29% 30-49% 50-69% 70-89% 90-100% 
SCORE 0 1 2 3 4 5 6 
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TABLE  - 3  
PASI SCORE – METHOD OF CALCULATION 
 
SCORE FOR THE LESION HEAD TRUNK 
UPPER 
EXTREMITIES 
LOWER 
EXTREMITIES  
& BUTTOCK 
INDURATION     
ERYTHEMA     
SCALING     
SUM=I+E+S     
% OF AREA AFFECTED      
AREA SCORE     
SUBTOTAL= AREA SCORE X SUM     
BODY AREA= SUBTOTAL X AMOUNT X 0.1 X 0.3 X 0.2 X 0.4 
TOTALS     
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PASI SCORE = HEAD + TRUNK + UPPER LIMB + LOWER LIMB 
PASI SCORE 
    PSORIASIS AREA  SEVERITY INDEX is a useful and important 
tool to calculate the severity of the disease and does not have specific cut 
off values. It is based on site of distribution , morphology of lesions and 
percentage of area of distribution
193
. 
INCLUSION CRITERIA 
Adults  with newly diagnosed  Psoriatic skin lesions  with age 20 to 
65 years. 
EXCLUSION CRITERIA 
Patients already diagnosed and undergoing  topical or systemic 
therapy psoriasis for less than two months prior to the study. 
                The biopsy was cut into two portions. Tissue is formalin fixed 
and  subjected to routine tissue processing. This is followed by 
haematoxylin and eosin staining and evaluated by light microscopy.  
Psoriasis was diagnosed by clinical features and confirmed by histology.  
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HAEMATOXYLIN AND EOSIN STAINING FOR ROUTINE 
HISTOLOGIC SECTIONS 
All specimens are fixed in 10%formalin , subjected to routine 
tissue processing  and 4-6 µm sections were cut on glass slides for routine 
Haematoxylin  and Eosin staining. 
REAGENTS  
1. Erhlich’s Haematoxylin solution 
2. Eosin Y solution 1% 
3. 1% acid alcohol solution 
PROCEDURE 
1. Sections are deparaffinised.  
2. Dip the sections in xylene for atleast 30 seconds. 
3. Place the section in isopropyl alcohol for fifteen minutes.  
4. Then the sections are washed under tap water.  
5. Sections are stained with Erhlich’s Haematoxylin for ten to fifteen 
minutes.  
6. Again sections are washed under tap water.  
7. Differentiation of sections in 1% acid alcohol solution by dipping 
the slide twice or thrice.  
8. Slide is kept for blueing for ten minutes. 
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9. Counterstaining with 1% eosin solution by dipping the slide twice 
or thrice followed by tap water wash.  
10. Sections are to be air dried.  
11. Dip in xylene and mount in DPX.   
             The routine hematoxylin and eosin stained sections are studied  
under  Olympus light microscope.and diagnosis of psoriasis was obtained 
by analysing histopathological features. 
 
IMMUNOHISTOCHEMISTRY  
This is a two step indirect technique based on detection of antigens in 
the cells and tissues. It is a two step process: 
1. Specific epitopes binds the primary antibody 
2. The following step is calorimetric reaction to detect the antigen 
antibody binding. 
REAGENTS IN IMMUNOHISTOCHEMISTRY 
1. Peroxide block which is 3% hydrogen peroxide in water 
2. Power block : Is a highly effective universal protein blocking agent. 
It consists of casein and propriety additives in PBS with 15Mm 
sodium azide. 
3. Chromogen : DAB – 3,3’- diaminobenzidine 
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4. Liquid DAB substrate buffer contains peroxide and stabilizers 
5. Superenhancer reagent 
6. Poly HRP reagent 
7. Mayer’s haematoxylin is used for counterstaining 
8. Buffer solutions. 
 
BUFFER SOLUTIONS 
TRIS BUFFER ( pH 7.6 ) 
      TRIS buffer salt  : 0.605 gm 
      Sodium chloride  : 8gm 
      Distilled water   : 1000 ml 
      1N Hydrochloric acid : 3ml 
     CITRATE BUFFER : (pH  6.0) 
          Trisodium citrate  :  2.94gm 
         Distilled water   : 1000ml 
         1N Hydrochloric acid : 5ml 
TRIS EDTA : (pH 9.0) 
         TRIS buffer salt  : 6.05gm 
         Disodium EDTA : 0.744gm 
         Distilled water : 1000ml 
 
72 
 
 
 
 
 
 
 
 
 
 
CHART – 1 : PRIMARY ANTIBODY WITH SECONDARY 
KIT 
PROCEDURE OF IMMUNOHISTOCHEMISTRY 
1. Sections are deparaffinised in xylene for 30 minutes.  
2. Sections are washed in absolute alcohol for five minutes with two 
changes followed by tap water wash for ten minutes.  
3. Sections are rinsed in distilled water for five minutes.  
4. Antigen retrieval is done by immersing slides in appropriate buffer 
solutions in microwave – medium mode for fifteen minutes and 
high mode 10 minutes.  
5. Cool to room temperature and then the slides are washed in 
distilled water.  
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6. The slides are washed in TBS buffer for five minutes with two 
changes. Sections are treated with peroxide block for ten minutes 
followed by wash in TBS buffer for five minutes with two changes.  
7. Treat with power block for ten minutes.  
8. Then drain the slides and cover the sections with primary antibody 
(supplied by biogenex) for one hour.  
9. This is followed by TBS buffer wash for five minutes with two 
changes. Cover the sections with superenhancer for 30 minutes.  
10. Wash in TBS buffer for five minutes with two changes. Cover the 
sections with poly HRP reagent for thirty minutes.  
11. Then again wash the slides with TBS buffer for five minutes with 
two changes. 
12. Sections are treated with DAB chromogen with substrate buffer for 
five to eight minutes.  
13. Wash in TBS buffer with two changes, each wash for five minutes.  
Wash the slides under tap water for five minutes.  
14. Counterstain the slides using Mayer’s Haematoxylin for one 
minute. Wash under tap water for five minutes. 
15. Slides are air dried and mount with cover slips using DPX 
mountant.  
     
74 
 
IMMUNOHISTOCHEMICAL EVALUATION     
The slides are examined under Olympus light microscope. The 
degree of immunohistochemical reactivity for VEGF and  VWFr  are 
evaluated based on  the level of staining of epidermis. They  are divided  
into three groups :    
(I) basal layer only - 1+   
(II) lower half of the epidermis- 2+ 
(III)  whole epidermis - 3+ .  
 VEGF and VWFr  shows cytoplasmic staining.  
The  evaluation of staining in     CD34 - microvessel densit y 
(MVD) was done  by capillary counting method  in the  3  highly 
vascularized areas selected also known as  hot spots, under 40x field.CD 
34 showed  membranous  and  cytoplasmic  staining. A  400x field was 
used to count microvessels in each of  the highly vascularised  areas. 
Single endothelial cell or clusters of endothelial cells,  either with or 
without lumen, were considered to be individual vessels. The score is  as 
follows:  
(I) Mild (4-10 capillaries) 
(II)  moderate (11-20 capillaries) 
(III)  severe (21-28 capillaries).   
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OBSERVATION AND RESULTS 
The present study was a prospective study conducted in the 
department of pathology during the period of  April 2013 to July 2014.  
Ethical clearance was obtained from the Ethics committee of Coimbatore 
medical college, Coimbatore. 
A total of 62 samples were obtained and studied which included 32 
cases of psoriasis vulgaris and 30 controls which is a normal healthy skin. 
Histopathological and immunohistochemical evaluation was done. Data 
was obtained , coded and entered into Microsoft excel spread sheet and 
analysed as below.  
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TABLE  -  4  
 AGE WISE  DISTRIBUTION  OF PSORIASIS 
 
AGE  DISTRIBUTION  n= 62 
AGE 
YEARS 
CASES CONTROL 
TOTAL 
MALE FEMALE MALE FEMALE 
<30 0 3 0 3 6 
31-40 5 2 3 1 11 
41-50 9 4 5 5 23 
51-60 4 4 8 4 20 
>60 0 1 0 1 2 
Total 18 14 16 14 62 
 
Among the 62 samples, maximum number  of samples belonged to 
age group of 41- 50 years of age followed by 51- 60 years of age.  
 
 
 
 
 
 AGE WISE DISTRIBUTION OF CASES AND CONTROLS.
CHART 2a 
CHART 2b 
Among the 62 samples, maximum number  of samples belonged to 
age group of 41- 50 years of age followed by 51
 
Male
<30 0%
31-40 16%
41-50 28%
51-60 13%
>60 0%
0%
5%
10%
15%
20%
25%
30%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
<30
Cases 9%
Control 10%
Age Distribution [N=62]
77 
- 60 years of age
Female Male
Experimental [n=32] Control[n=30]
9% 0%
6% 10%
13% 17%
13% 27%
3% 0%
Age Distribution   (N=62)
31-40 41-50 51-60
22% 41% 25%
13% 33% 40%
 
 
 
.  
Female
10%
3%
17%
13%
3%
>60
3%
3%
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TABLE-  5 
MEAN AGE WITH GENDER DISTRIBUTION 
 
 
GROUP Gender Mean SD Lower Upper Minimum Maximum 
 
Cases 
 
Male 46 8 42 49 33 59 
  
 
  
  
 
  
Female 44 11 38 51 27 63 
Total 45 9 42 48 27 63 
 
Controls 
 
Male 49 9 44 53 34 58 
Female 45 12 38 51 26 61 
Total 47 10 43 51 26 61 
 
 
In the present study of  62 samples (32 cases and 30 controls), 
mean  age  of  distribution  is  45 years. Among the cases  maximum 
number of patients  belonged to 41 to 50 years of age (41%) and 
maximum number of controls belonged to 51 – 60 years(40%)(chart 1). 
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TABLE -  6 
GENDER WISE DISTRIBUTION OF SAMPLES 
 
Gender Cases Controls 
Male 18 16 
Female 14 14 
Total 32 30 
 
In the present study among cases male to female ratio was1.2:1 . 
Among controls male to female ratio was 1.1:1. 
 
 
 
 
 
 
 
 
 
  
GENDER  WISE DISTRIBUTION OF PSORIASIS
 
 
 In the present study among cases male to female ratio was1.2:1
with male predominance
was 1.1:1. 
 
 
 
Experimental [n=32]
Male
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CHART -  3 
 . Among controls male to female ratio 
Control[n=30]
56%
44%
Sex Distribution[N=62]
 
 
 
                     
53%
47%
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TABLE  - 7  
 
 MICROVESSEL DENSITY  - EVALUATION  OF                                
CD 34 STAINING 
 
CD34 Cases Control Total (%) 
Neg 0 23 23 37% 
1+(mild) 0 7 7 11% 
2+(moderate) 23 0 23 37% 
3+(severe) 9 0 9 15% 
Total 32 30 62 100% 
    
CD 34 expression was seen in all samples from psoriatic skin 
lesions with various intensities. CD34 expression was weak in all control 
skin samples. Among cases 72% of skin samples showed moderate 
degree of staining. 
 
 
 
 
 
  
 INTENSITY OF CD34 STAINING AMONG CASES
 
 
Among cases 72% of skin samples showed moderate degree of 
staining for CD 34.
 
 
 
3+
28%
82 
CHART  - 4a 
 
2+
72%
CD34 -cases group [n=32]
 
 
 COMPARISON OF IMMUNOREACTIVITY OF CD 34  
BETWEEN CASES AND CONTROL
 
 
CD34 expression was weak in all control skin 
controls 23% showed weak positivity.
showed moderate degree of stainin
staining. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Group Cases
Group Control
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CHART  -  4b 
 
samples
 Among cases 72% of skin samples 
g and 28% with higher intensity of 
Neg 1+ 2+
0% 0% 72%
77% 23% 0%
CD34 [N=62][p<0.01]
 
 .among 
3+
28%
0%
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TABLE -  8 
IMMUNOHISTOCHEMICAL STAINING OF VEGF 
 
VEGF Cases Control Total (%) 
Neg 0 23 23 37% 
1+ 0 7 7 11% 
2+ 12 0 12 19% 
3+ 20 0 20 32% 
Total 32 30 62 100% 
 
VEGF expression was seen in all cases and weak staining in 
controls. 63% of cases showed diffuse staining of full thickness of 
epidermis with only 23% of controls showing weak positivity of 
epidermis. 
 
 
 
 
 
 
  
IMMUNOREACTIVITY OF VEGF AMONG CASES
 
63% of cases showed diffuse staining of VEGF involving 
thickness of epidermis
 
 
 
 
3+
63%
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CHART  5a 
 
 
VEGF -cases group [n=32]
 
 
 full 
2+
37%
  
COMPARISON OF VEGF EXPRESSION 
 
VEGF expression was seen in all cases with a
controls. 63% of cases showed diffuse staining of full t
epidermis with only 23% of controls showing weak positivity
epidermis. 
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CHART  - 5b  
BETWEEN CASES AND 
CONTROL 
 
 weak staining in 
Neg 1+ 2+
0% 0% 38%
77% 23% 0%
VEGF [N=62][p<0.01]
 
hickness of 
 in 
3+
63%
0%
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TABLE  - 9 
 
IMMUNOHISTOCHEMICAL EVALUATION OF 
VONWILLEBRAND FACTOR 
VWFr Cases Control Total (%) 
Neg 21 20 41 66% 
1+ 11 10 21 34% 
Total 32 30 62 100% 
 
Vonwillebrand factor showed similar weak epidermal  expression 
in both cases and control group. Cases with negative staining were 66% 
and 67% of controls showed negative expression. 
 
 
 
 
 
 
  
INTENSITY OF VWFr STAINING AMONG CASES
 
Cases with negative staining
 
 
 
 
 
1+
34%
VWFr 
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CHART  - 6a  
 
 for vonwillebrand factor 
-cases group [n=32]
 
 
 were 66% 
Neg
66%
 COMPARISON OF VWFr EXPRESSION BETWEEN CASES AND 
 
Vonwillebrand factor showed similar 
expression in both case group and control group. Cases with negative 
staining were 66% and 67% of controls showed negative expression
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CHART -  6b 
CONTROL 
 
 type of 
Neg 1+
66% 34%
67% 33%
VWFr[N=62][p>0.05]
 
weak epidermal  
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TABLE - 10 
MEAN OF  ANGIOGENIC  FACTOR  EXPRESSION 
 
I. Mean expression of CD 34 among cases was 2.3 +/-0.5 SD and 
among controls 0.2+/- 0.4SD. 
II. Mean expression of  VEGF among cases was 2.6 +/0.5- SD and 
among controls 0.2+/- 0.4SD. 
III. Mean expression of VWFr among cases was 0.34 +/-0.48 SD and 
among controls 0.33+/- 0.48SD. 
 
 
 
Factors Group Mean SD Lower Upper Minimum Maximum 
P 
value 
PASI Case 16.2 1.9 15.5 16.9 13.8 19.6   
 
CD34 
 
Case 2.3 0.5 2.1 2.5 2.0 3.0 
  
< 0.05 
  
Control 0.2 0.4 0.1 0.4 0.0 1.0 
Total 1.3 1.1 1.0 1.6 0.0 3.0 
 
VEGF 
 
Case 2.6 0.5 2.5 2.8 2.0 3.0 
  
<0.05 
  
Control 0.2 0.4 0.1 0.4 0.0 1.0 
Total 1.5 1.3 1.1 1.8 0.0 3.0 
VWFr 
 
Case 0.34 0.48 0.2 0.5 0.0 1.0 
  
> 0.05 
  
Control 0.33 0.48 0.2 0.5 0.0 1.0 
Total 0.3 0.5 0.2 0.5 0.0 1.0 
 PSORIASIS AREA 
       Most of the cases belonged to the PASI score ranging
 
 
 
 
 
>17.0
44%
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CHART  - 7 
 
PASI SCORE – IN CASES 
 SEVERITY INDEX
 
13.1
15.1-17.0
19%
PASI score [n=32]
 
 
 from  13.1 to 15. 
-15.0
37%
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TABLE – 11    
AGE Vs PASI SCORE 
      
 
PASI Score 
Age 13.1-15.0 15.1-17.0 >17 Total 
<30 
 
1 2 0 3 
31-40 
 
1 0 6 7 
41-50 
 
6 3 4      13 
     
51-60 4 1 3 8 
 
>60 
 
0 0 1 1 
Total 12 6 14 32 
 
       The mean PASI score in the present study was 16.2+/-1.9 
 
 
 
 
 
 
 
  
The mean PASI score in the present study was 
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CHART 8 
 AGE Vs PASI SCORE 
 
16.2+/
31-40 41-50 51-60
3% 19% 13%
0% 9% 3%
19% 13% 9%
PASI score vs Age[n=32][p>0.05]
 
-1.9 
>60
0%
0%
3%
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TABLE   -  12  
 
 CORRELATION BETWEEN PASI SCORE AND ANGIOGENIC 
FACTORS 
 
  
PASI 
Score 
CD 34 VEGF VWFr. 
PASI 
Score 
Pearson 
Correlation 
1 .942
**
 .944
**
 0.024 
Sig. (2-tailed) 
 
0.000 0.000 0.855 
N 62 62 62 62 
CD 34 
Pearson 
Correlation 
.942
**
 1 .879
**
 0.058 
Sig. (2-tailed) 0.000 
 
0.000 0.653 
N 62 62 62 62 
VEGF 
Pearson 
Correlation 
.944
**
 .879
**
 1 -0.022 
Sig. (2-tailed) 0.000 0.000 
 
0.866 
N 62 62 62 62 
VWFr. 
Pearson 
Correlation 
0.024 0.058 -0.022 1 
Sig. (2-tailed) 0.855 0.653 0.866 
 
     N 62 62 62 62 
  
There was significant  correlation between expression of  
angiogenic factors and psoriatic area and severity index(PASI Score) 
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CHART  - 9 
CORRELATION BETWEEN PASI  AND CD34 
 
 
 
There is significant correlation between expression of CD34 with  
psoriatic area snd severity index score and it was statistically significant. 
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CHART  - 10 
 CORRELATION BETWEEN PASI  AND VEGF 
 
 
There is a significant correlation between  expression of VEGF  
with  psoriatic area snd severity index score and it was statistically 
significant. 
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CHART - 11 
CORRELATION BETWEEN PASI  AND VWFr 
 
 
There is no statistically significant correlation between expression 
vWFr with PASI score. 
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STATISTICAL ANALYSIS 
 
Data obtained was coded and entered into Microsoft  excel spread 
sheet. The data are reported as the mean +/- SD or the median , depending 
on their distribution. Qualitative  variables were presented as number and 
percent. The differences in quantitative variables between groups were 
assessed by means of the unpaired t test. Comparison between groups 
were made by the Non parameteric  Mann – whitney  test. A chisquare 
test was used to assess differences in categoric  variables between groups. 
Pearson’s coefficients of correlation was used to assess the relationship 
between the variables.     
A p value of <0.05 using a two tailed test was taken as being 
significance for all statistical tests. 
All data were analysed with a statistical software package (SPSS, 
version 16.0 for windows) 
  
  

  
    
                                 
                    
                         
                                  
 
 
   
FIG  1
1  - stratum basale
2 -         stratum spinosum
3 - stratum 
4 - stratum corneum
5 - dermal capillaries
 
    
   
 
 
 
          
 
 
 NORMAL HISTOLOGY OF SKIN
 
 
 
granulosum 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
FIG  2
 
 
1  - hyperkeratosis with munro s abscess
2 -         psoriasiform hyperplasia 
3 - dilated and tortuous dermal capillaries
 
 
 HISTOPATHOLOGY OF PSORIASIS
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 – DILATED DERMAL CAPILLARIES IN PSORIASIS 
FIG 4: IHC SHOWS LOW POWER 
EPIDERMAL  
FIG 5 : IHC HIGH POWER  SHOWS  MODERATE  DEGREE OF 
EPIDERMAL STAINING (2+) IN CASES
- VEGF  MODERATE  
 POSITIVITY (2+)  IN CASES
 
 
 
 
FIG 6 : IHC LOW
STAINING  
FIG 7 : IHC HIGH POWER SHOWS CYTOPLASMIC AND 
MEMBRANOUS POSITIVITY 
 POWER SHOWS DIFFUSE  EPIDERMAL  
OF VEGF (3+ POSITIVITY) IN CASES
- HIGHER DEGREE (3+)  IN 
CASES 
 
 
 
 
FIG 8: IHC  LOW POWER 
EPIDERMAL STAINING (1+)  IN 
 
FIG 9 IHC HIGH POWER SHOWS WEAK  EPIDERMAL 
POSITIVITY 
 
- SHOWS  VEGF  WEAK 
CONTROLS
 OF VEGF  (1+)  IN CONTROLS
 
 
 
 
FIG  10: IHC LOW POWER VIEW SHOWS CD34 POSITIVITY IN 
FIG 11: IHC HIGH POWER VIEW SHOWS CD 34 MILD 
CASES 
POSITIVITY (1+) IN CASES 
 
FIG 12: IHC HIGH POWER VIEW
DEGREE OF POSITIVITY (2+) IN  CASES
FIG :13 IHC HIGH POWER VIEW SHOWS HIGHER  DEGREE 
OF POSITIVITY (3+) IN  CASES
 
 SHOWS MODERATE 
 
 
 
 
 FIG 14: LOW POWER SHOWS WEAK EPIDERMAL STAINING 
OF VON WILLE BRAND FACTOR IN CASES
FIG 15: HIGH POWER SHOWS WEAK EPIDERMAL STAINING 
OF VON WILLE BRAND FACTOR IN 
 
 CASES
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                                              DISCUSSION 
 
Psoriasis is an autoimmune chronic inflammatory dermatological 
disease. It affects people of all age groups. In case of genetic transmission 
it can have onset in early adulthood. Clinically psoriasis vulgaris which is 
a chronic plaque type of skin lesion presenting as raised, reddish scaly 
lesion.. Histopathologically , psoriasis is characterised by hyperkeratosis, 
parakeratosis, epidermal hyperplasia spongiform pustules of kogoj, 
suprapapillary thinning of granular layer, inflammatory infiltrate in 
dermis and capillary proliferation in dermis.  
The pathogenesis is yet to be elucidated. Various factors seem to 
play a pathogenetic role in psoriasis. They are immune mediated aberrant 
regulation of  T lymphocytes, interaction between rapidly proliferating 
epidermal cells and an array of cytokines, angiogenesis, 
neovascularisation and vascular remodelling. Several studies show that 
rapidly proliferating keratinocytes seem to secrete certain cytokines and 
angiogenic factors such as VEGF. Angiogenesis refers to development  of 
new blood vessels from the preexisting vascular channels. In  Psoriasis 
there is marked increase in endothelial microvasculature thus supporting 
that psoriasis is angiogenesis dependent. Microvascular expansion in 
dermis with abnormal dilatation and orientation of capillaries in skin 
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biopsy in psoriasis patients signifies the importance that psoriasis is 
angiogenesis dependent. Psoriasis was studied in the light of  its 
angiogenic nature .  
The keratinocytes in psoriasis skin lesion are considered to be a 
source of  proangiogenic cytokines like  vascular endothelial growth 
factor, tumor necrosis factor alpha, endothelial cell stimulating factor and 
platelet derived growth factor. There are newer angiogenic factors namely 
vWFr- von willebrand factor, NGF – nerve growth factor
9
. These 
cytokines stimulate angiogenesis in psoriatic skin lesions.   
The present study encompasses  the immunohistochemical 
expression of  angiogenic factors and angiogenic markers in cases and 
controls. The present evaluates the neovasularisation and vascular 
changes in psoriatic skin lesions. 
           In the present study the mean age of occurence for the cases was    
45   years and mean age of  for the  controls  was  47  years. In a similar 
study done  by Siaw – Cheok
9
 et al , the mean age of occurrence  for the 
cases was 47.94 years and mean age for the controls was 42.33 years. In 
another study done by Moorchung et al
194
 the mean age  was 38.9 years 
for cases. . 
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          In the present study there were 18 males and 14 females  among 
cases and among controls there were 16 males and 14 females. In a study 
done by Moorchung et al
194
 there were 48 males and 40 females among 
cases. 
            In the present study the average PASI score for cases was 16.2+/-
1.9. In a similar study done  by Siaw- Cheok et al
9
 the average PASI 
score was 7.247+/-4.780. 
          In the our  study VEGF expression was observed in all cases with 
various intensities. VEGF expression was weak in most of the controls. 
VEGF expression was significantly higher  in cases compared to controls 
with a statistical significant difference (p=<0.05) . Similar results were 
observed in the following studies.  
According to a study conducted by Siaw – Cheok
9
 et al  intensity 
of  VEGF expression was higher in cases compared to controls(p=0.016).  
Simonetti et al
7
  observed that there was diffuse VEGF(13.15+/- 6.6) 
immunohistochemical expression in epidermis of psoriatic skin lesions 
compared to epidermis of normal skin.  
In another study done  by Rashed et al
195
 ,there was strong VEGF 
expression in epidermis(mean46.1+/-19.66) and a moderate expression in 
vessels and inflammatory infiltrates(mean 19+/-5.4 and 8+/-2.16).VEGF 
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expression was significantly higher in skin of psoriasis cases compared to 
normal healthy controls. In a similar study conducted by Kim YG et al
196
 
the expression of VEGF was significantly enhanced in skin of psoriasis 
cases compared normal healthy controls.  
The  above  studies correlates with our study and also  shows  that 
VEGF promotes endothelial cell survival , promotes new blood vessel 
formation and thus plays a significant role in pathogenic basis  of 
psoriasis. It appears to be one of the important factor in pathomechanism 
of psoriasis. Bhushan et al reported  that VEGF was mainly produced by 
epidermal keratinocytes compared to fibroblast
130
. 
In the present study there was significant correlation between the 
expression of VEGF with PASI score.(r=0.944, p=<0.05) 
In a  study conducted by Siaw – Cheok
9
 et al  there was no 
significant correlation between PASI score and VEGF(p=0.232). 
In the present study expression of CD 34 was observed in all 
samples of  psoriasis  with variable intensities , whereas CD 34 
expression in controls was weak. There was significantly higher 
expression of CD 34 in cases compared to controls which is statistically 
significant(p=<0.01).  
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In a study done by Amin et al
197
 ,they observed that CD 34 
expression was higher in cases than controls with a statistically 
significant difference(Z=2.1,p=0.04) and  expression  of CD 34 was 
significantly higher in psoriatic lesion skin compared to non lesional skin. 
In another study by Gupta S et al
198
 showed that microvascular staining in 
dermis of psoriatic skin lesions was higher. Also microvessel density was 
higher in skin of psoriasis(71.28+/- 40.05).  
A study conducted by Barton et al
199
 showed that there is higher 
endothelial volume and volume of lumen in the skin of psoriatic lesions 
compared to non lesional skin of psoriasis and healthy skin of controls. In 
a study done by Simonetti   O et al
7
, CD 34 was expressed significantly 
higher in skin of psoriatic lesions compared to controls.(19.15+/-12.61 vs 
3.0+/- 0.23; p=0.04)  
The above studies supports our observation and  indicates that in 
psoriasis there is vascular proliferation, tortuosity and elongation of 
vessels in response to inflammation reflected by  increased microvessel 
density. 
In the present study there was significant correlation between the 
expression of CD 34  with PASI score(r=0.942;p=<0.05). In a similar  
study  by  Gujiao BI et al
200
 indicated that CD 34 expression was 
increased in vascular endothelial cells in dermis of psoriatic skin lesions 
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and might be related to severity of psoriasis.CD34 might be involved in 
adhesion and migration of inflammatory cells.  
In the present study expression of vWFr   both  in  lesional skin and 
control skin was weak. There was no statistically significant 
difference(p=>0.05). In a similar study conducted by Siaw – Cheok
7
 et al  
there was no expression of vWFr in psoriatic cases. In the present study 
there was no statistically significant correlation between PASI Score and 
vWFr(r=0.024;p=>0.05). In a similar study conducted by Siaw – Cheok
7
 
et al  there was no significant correlation between PASI score and vWFr 
(p=0.169). 
   The above studies indicates that angiogenesis plays a key and  
central  role in pathogenesis of psoriasis. Other evidences which support 
that angiogenesis is seen in psoriasis are the following  
I. enhanced blood flow in psoriasis skin biopsy using laser Doppler 
fluxmetry 
II. increased microvasculature in the psoriatic skin lesion seen in 
autoradiograph and  
III.  the ultrastructural studies which shows tortuous and elongated 
capillary loops in lesional psoriatic skin. 
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Various other studies are being done elsewhere regarding 
immunohistochemical expression of angiogenesis markers and 
angiogenic factors in psoriatic skin lesions. It includes nerve growth 
factor, survivin, iNOS, basic fibroblast factor
195
 and a pleiotropic 
osteopontin
197
.    
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SUMMARY  
Psoriasis is a chronic inflammatory dermatological condition which 
is a chronic disabling disease. Both the keratinocytes and T lymphocytes 
secrete these angiogenic factors which is responsible for 
neovascularisation in psoriasis.  Angiogenesis and inflammatory 
infiltration might be interdependent in psoriasis. The present study was 
undertaken to analyse to  analyse  immunohistochemical expression of  
angiogenic factors Vascular  endothelial growth factor, Von wille brand  
factor and CD 34 in skin biopsy of patients with psoriasis vulgaris and 
controls and to correlate with psoriasis area and severity clinical 
index(PASI SCORE). 
VEGF expression in epidermis was significantly higher in cases 
when compared to control skin (p=<o.o1).CD 34 expression was 
significantly upregulated in cases when compared to controls.(p<0.01). 
Whereas only weak expression of vonwillebrand factor was observed in 
both cases and controls. Significant correlation between the expression of 
VEGF and PASI score(r=0.944;p<0.05), and expression of CD 34 and 
PASI score was observed(r=0.942;p<0.05). 
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CONCLUSION 
The present study titled as “Differential expression of angiogenic 
factors in skin of patients with psoriasis vulgaris” was conducted in 
Department of Pathology from April 2013 to July 2014”. 
Our study demonstrated significantly higher expression of 
angiogenic factor – VEGF( vascular endothelial growth factor) and 
angiogenesis marker CD 34 in psoriatic skin lesions. But  expression of  
von willebrand factor was not statistically significant. Significant  
correlation was also noted between PASI score and expression of VEGF 
and CD 34. Hence antiangiogenic therapy may be useful therapeutic 
approach in psoriasis.  
              Various other studies are being done elsewhere regarding 
immunohistochemical expression of angiogenesis markers and 
angiogenic factors in psoriatic skin lesions. It includes nerve growth 
factor, survivin, iNOS, basic fibroblast growth factor and a pleiotropic 
osteopontin 
Future research with larger samples could be done to analyse in 
detail the angiogenic pathways  for development  of  targeted anti- 
angiogenic therapy which might be beneficial for this chronic disabling 
disease. 
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 ANNEXURE  -  I  
PROFORMA 
 
(I)PATIENT  INFORMATION 
• NAME 
• AGE(YEARS) 
• SEX 
• IP/OP NUMBER 
• OCCUPATION 
• ADDRESS 
 
(II)CLINICAL  INFORMATION 
• DURATION OF LESIONS 
• SITE OF DISTRIBUTION 
• AREA OF DISTRIBUTION 
• FEATURES OF LESION- ERYTHEMA,INDURATION,SCALING 
• PSORIATIC AREA AND SEVERITY INDEX 
• TREATMENT TAKEN OR TAKEN; IF TAKEN – DURATION OF 
TREATMENT , SYSTEMIC OR TOPICAL 
 
(III)SITE OF BIOPSY SPECIMEN ; NUMBER  AND SIZE OF BIOPSY 
SPECIMEN 
 
(IV)MICROSCOPIC FINDINGS 
• H& E DIAGNOSIS 
• IHC FINDINGS 
 
  
                                           CONSENT FORM 
Dr..S.Lakshna, postgraduate student in the department of 
pathology, Coimbatore Medical College is conducting a study on 
“DIFFERENTIAL EXPRESSION OF ANGIOGENIC FACTORS IN 
SKIN OF PATIENTS WITH PSORIASIS VULGARIS”. A skin 
biopsy involves removal of a small piece of skin under local 
anaesthesia.The piece of skin is then processed and examined under a 
microscope to obtain diagnostic information or is tested for other studies. 
I have been informed ,to my satisfaction regarding the nature of 
procedure. The data used herein may be used for research and 
publication. The data used herein may be used for research and 
publication.  
 
Name   : 
Place   : 
Signature  : 
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ANNEXURE  - II  
MASTER  CHART FOR  CASES 
S.NO HPE NO IP/OP NO AGE SEX PASI Score CD 34 VEGF VWFr. 
1 385/13 461035 30 F 16.4 2+ 2+ 1+ 
2 355/13 41299 35 M 17.2 2+ 3+ 1+ 
3 375/13 40910 33 M 17.4 2+ 3+ 1+ 
4 582/13 40898 48 F 14.6 2+ 2+ 1+ 
5 583/13 3851 53 F 16.4 2+ 3+ NEG 
6 682/13 32554 52 M 18.8 3+ 3+ 1+ 
7 1180/13 38505 55 M 18 2+ 3+ 1+ 
8 1617/13 37205 47 M 18.8 3+ 3+ NEG 
9 1588/13 45944 29 F 16.4 2+ 2+ NEG 
10 2749/13 46407 63 F 17.2 2+ 3+ NEG 
11 2843/13 6684 55 F 19.6 3+ 3+ NEG 
12 2845/13 6189 45 M 18 3+ 3+ 1+ 
13 2221/13 39179 47 F 16.4 2+ 3+ NEG 
14 2222/13 38487 38 M 17.2 2+ 3+ NEG 
15 900/13 38891 31 F 17.4 3+ 3+ NEG 
16 971 /13 40582 27 F 13.8 2+ 2+ 1+ 
                                                              
VEGF AND vWFr - basal layer only - 1+ ; lower half of the epidermis- 2+;  whole epidermis - 3+ ; 
CD 34- Mild (4-10 capillaries) 1+;  moderate (11-20 capillaries)2+; severe (21-28 capillaries)3+ 
                                                  
S.NO HPE NO IP/OP NO AGE SEX PASI Score CD 34 VEGF VWFr. 
17 335/14 3880 43 F 14.8 2+ 3+ NEG 
18 679/14 47001 42 M 14 2+ 3+ NEG 
19 784/14 41511 44 M 15.2 2+ 3+ 1+ 
20 1048/14 40200 56 F 14 2+ 3+ NEG 
21 1096/14 41904 58 M 13.8 2+ 2+ NEG 
22 2100/14 35611 49 M 14 2+ 2+ NEG 
23 2425/14 41322 44 M 16.4 2+ 3+ NEG 
24 1495/14 13891 51 F 14.6 2+ 2+ NEG 
25 1121/14 50543 50 M 19.6 3+ 3+ NEG 
26 1505/14 41543 39 F 18 3+ 3+ 1+ 
27 1872/14 32653 49 M 14.08 2+ 3+ NEG 
28 1647/14 38912 59 M 14.06 2+ 2+ 1+ 
29 1800/14 24890 38 M 13.8 2+ 2+ NEG 
30 2639/14 26765 48 F 13.8 2+ 2+ NEG 
31 3011/14 24797 36 M 17.4 3+ 3+ NEG 
32 3233/14 44645 47 M 17.8 3+ 2+ NEG 
 MASTERCHART FOR CONTROLS 
S.NO HPE NO IP/OP NO Age PASI Score Sex VEGF CD34 VWFr. 
1.  1760/13 9959 31 NA F neg neg neg 
2.  1833/13 11544 36 NA M neg neg neg 
3.  842/13 131652 34 NA M neg neg neg 
4.  908/13 12536 47 NA F 1+ 1+ 1+ 
5.  2006/13 5665 54 NA F neg neg neg 
6.  2053/13 10209 53 NA M neg neg 1+ 
7.  977/13 9418 56 NA M neg 1+ neg 
8.  1076/13 6278 46 NA M 1+ neg 1+ 
9.  947/13 10932 28 NA F neg neg neg 
10.  1200/13 11512 61 NA F neg 1+ neg 
11.  1406/13 9583 53 NA F 1+ neg 1+ 
12.  1411/13 8079 45 NA M neg neg neg 
13.  1860/13 9667 48 NA F neg 1+ neg 
14.  3626/13 7997 38 NA M neg neg 1+ 
15.  3711/13 5957 30 NA F neg neg neg 
 
 
 S.NO HPE NO IP/OP NO Age PASI Score Sex VEGF CD34 VWFr. 
         16. 559/14 10930 26 NA F 1+ 1+ neg 
17. 624/14 240221 42 NA F neg neg neg 
18. 61/14 2473 43 NA M neg neg 1+ 
19. 920/14 19224 41 NA M 1+ neg neg 
20. 115/14 10010 54 NA F neg 1+ neg 
21. 509/14 18231 58 NA M neg neg 1+ 
22. 337/14 18555 56 NA M neg 1+ neg 
23. 429/14 16838 43 NA F 1+ neg 1+ 
24. 278/14 18878 47 NA M neg neg neg 
25. 211/14 18902 57 NA M neg neg neg 
26. 1119/14 10786 58 NA M neg neg 1+ 
27. 1178/14 243977 59 NA F 1+ neg neg 
28. 2760/14 18162 55 NA M neg neg neg 
29. 2955/14 20766 49 NA F neg neg 1+ 
30. 3122/14 240218 58 NA M neg neg neg 
 
VEGF AND vWFr - basal layer only - 1+ ; lower half of the epidermis- 2+;  whole epidermis - 3+ ; 
CD 34- Mild (4-10 capillaries) 1+;  moderate (11-20 capillaries)2+; severe (21-28 capillaries)3+ 
  
 
ABBREVIATIONS  FOR  MASTER CHART 
 
 
   M    – MALE 
   F   – FEMALE 
  NA   –  NOT APPLICABLE 
  VEGF  –  VASCULAR ENDOTHELIAL; GROWTH FACTOR 
   vWFr   –  VON WILLEBRAND FACTOR 
 PASI SCORE –  PSORIASIS AREA SEVERITY INDEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEXURE III 
ABBREVIATIONS 
 
VEGF    –   Vascular endothelial growth factor 
Th    –  T helper cell 
VWFr  –  Vonwillebrand factor 
PASI SCORE –  Psoriasis area severity index 
IL   –  Interleukin 
HLA   –  Human leucocyte antigen 
TNF alpha  –  Tumor necrosis factor alpha 
IFN gamma  –   Interferon gamma 
NSAIDs   –  Nonsteroidal anti inflammatory drugs 
APC    –    antigen– presenting cells 
KGF   –   keratinocyte growth factor  
TCR   –   T cell receptor 
MHC   –   Major histo compatibility complex 
GMCSF  –   Granulocyte macrophage colony stimulating  
    factor  
EGF    –  Epidermal growth factor 
NFkb   –   Nuclear factor kappa beta 
LFA   –   Lymphocyte function associated antigen 
ICAM   –   Intercellular adhesion molecule 
TSP    –  Thrombospondin 
 
ANG    –  angiopoietin 
HIF   –   Hypoxia inducible factor 
EC   –   endothelial cell 
ECM   –   extracellular matrix 
MMP   –   Matrixmetalloproteinases 
TGF alpha  –   Transforming growth factor 
VEGFR  –   Vascular endothelial growth factor 
RNA    –  Ribonucleic acid 
HIV   –   Human immunodeficiency virus 
AIDS   –  Acquired immunodeficiency virus 
LCH    –  Langerhans cell histiocytosis 
I   –  Induration 
E   –   Erythema 
S   –  Scaling 
H & E  –  Haematoxylin and eosin 
DAB    –  3,3’–  diaminobenzidine 
PBS    –  Phosphate buffer saline 
 
 
 
 
 
 
 
